WO2022242398A1 - Pretreatment reagent, preparation method, cell staining method and pretreatment method - Google Patents

Pretreatment reagent, preparation method, cell staining method and pretreatment method Download PDF

Info

Publication number
WO2022242398A1
WO2022242398A1 PCT/CN2022/087803 CN2022087803W WO2022242398A1 WO 2022242398 A1 WO2022242398 A1 WO 2022242398A1 CN 2022087803 W CN2022087803 W CN 2022087803W WO 2022242398 A1 WO2022242398 A1 WO 2022242398A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
pretreatment
staining
pretreatment reagent
phosphate
Prior art date
Application number
PCT/CN2022/087803
Other languages
French (fr)
Chinese (zh)
Inventor
王志平
刘亚慧
Original Assignee
深圳安侣医学科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳安侣医学科技有限公司 filed Critical 深圳安侣医学科技有限公司
Publication of WO2022242398A1 publication Critical patent/WO2022242398A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

Definitions

  • the present application belongs to the technical field of cell staining, and in particular relates to the cell staining technology in the state of suspension, especially to the method and reagents for pre-treatment of cell staining in the state of suspension.
  • cell staining techniques are usually used to distinguish cells of different types, shapes, and states.
  • the sample to be tested is usually smeared on a transparent carrier such as a glass slide. After the dyeing is evenly completed, the main body of the dye solution and buffer solution that affect the observation is washed away, and the dyed sample is dried after waiting for the entire dyeing process to form a stained sample smear for bright field observation.
  • the dry film staining steps in the prior art are extremely cumbersome and time-consuming, and the staining efficiency is extremely low, making it impossible to stain sample cells in large quantities. And the operation of each step requires well-trained professional operators in order to produce qualified observation samples. In addition, it takes a long time to dye the dry film and the efficiency is low, and the cost efficiency cannot meet the actual needs when testing a large number of samples.
  • CAS number (CASRegistryNumber or CASNumber, CASRn, CAS#), also known as CAS registration number or CAS registration number, is the unique digital identification of a certain substance (compound, polymer material, biological sequence (Biological sequences), mixture or alloy) Number. It is constructed by the Chemical Abstracts Service (CAS) under the American Chemical Society. The agency is responsible for assigning a CAS number to each substance that appears in the literature, which avoids the trouble of having multiple names for chemical substances and makes the database search more convenient.
  • Purified water refers to the water that meets the purified water standard of "Chinese Pharmacopoeia (2015 Edition)". Its main parameters are: the pH value is between 4.4 and 7.6, and the off-line conductivity meter is used to detect it. Water with a conductivity not greater than 25 ⁇ S/cm (micro Siemens per centimeter) at 10 ml (milliliter).
  • Regis staining solution refers to the liquid dyeing solution formed by using eosin, methylene blue and azure as the main dyeing substances after certain processing technology.
  • Giemsa staining solution Product No. BA-4017 from Zhuhai Beisuo Biotechnology Co., Ltd.
  • Wright's staining solution refers to the dyeing solution formed by using eosin and methylene blue as the main dyes, dissolving, mixing, and chemically acting in a certain organic solvent.
  • Wright's staining solution article number G1040 of Beijing Suolaibao Technology Co., Ltd.
  • Giemsa dyeing solution refers to the dyeing solution formed after the main dyes are acid eosin and azure, which are dissolved, mixed and chemically reacted by certain organic solvents.
  • Giemsa staining solution Product No. BA-4219 from Zhuhai Beisuo Biotechnology Co., Ltd.
  • New methylene blue dyeing solution refers to the dyeing solution formed by using new methylene blue as the main dye and dissolving it in a certain organic or inorganic solvent.
  • Giemsa staining solution Product No. BA-4003 from Zhuhai Beisuo Biotechnology Co., Ltd.
  • Brilliant tar blue dyeing solution refers to a dyeing solution formed by dissolving brilliant cresyl blue as the main dye in a certain organic or inorganic solvent. Such as Wright's staining solution (product number G1410) of Beijing Soleibao Technology Co., Ltd.
  • Diff's dyeing solution refers to the dyeing solution formed by a certain process with water-soluble eosin, melanin and azure II as the main dyes and water as the main solvent.
  • Wright's staining solution product number G1541 of Beijing Suo Laibao Technology Co., Ltd.
  • the technical problem to be solved in this application is to avoid the above-mentioned shortcomings of the prior art, and propose a simple and efficient pretreatment reagent and preparation method, a cell staining method and a pretreatment method.
  • the pre-treatment adjusts the cell state to a state suitable for suspension staining, which is very suitable for large-scale and batch sample cell staining.
  • the technical scheme of the present application to solve the above-mentioned problems is a pretreatment reagent used for pretreatment of cells stained in suspension, and its components, by volume percentage, include 0.5%-5% stabilizer, 95%-99.5% buffer liquid.
  • the stabilizer in this solution on the one hand, cross-links the membrane proteins on the cell membrane surface to form a network structure on the cell membrane surface to maintain the cell shape; on the other hand, it destroys the phospholipid bilayer of the cell membrane and increases the permeability of the cell membrane.
  • the efficiency of subsequent dyes entering the cells is consistent and fast; the time for cell staining is shortened, and the uniformity of staining becomes higher.
  • the components of the pretreatment reagent include 1%-3% stabilizer and 97%-99% buffer in volume percentage.
  • the components of the pretreatment reagent include 1.75% stabilizer and 98.25% buffer in volume percentage.
  • the pH value range of the pretreatment reagent is 6.5-8.1; or the pH value range of the pretreatment reagent is 6.8-7.6.
  • the components of the stabilizer, by volume percentage include 33.3%-50% glutaraldehyde solution, 50%-66.7% aldehyde solution; or the components of the stabilizer, by volume percentage, include 40% -50% glutaraldehyde solution, 50%-60% aldehyde solution.
  • the components of the stabilizer include, by volume percentage, 42.9% glutaraldehyde solution and 57.1% formaldehyde solution.
  • the aldehyde substances in the aldehyde solution include any one or more of formaldehyde, acetaldehyde, propionaldehyde and paraformaldehyde.
  • the components of the stabilizer include, by volume percentage, 21.1%-48.3% glutaraldehyde solution and 51.7%-88.9% alcohol solution.
  • Alcohol substances in the alcohol solution include absolute methanol or absolute ethanol.
  • the glutaraldehyde solution is a glutaraldehyde solution with a mass percentage of glutaraldehyde of 50%; the aldehyde solution is an aldehyde solution with a mass percentage of aldehydes of 37%.
  • the formaldehyde solution is a formaldehyde solution with a mass percent of formaldehyde of 37%.
  • the components of the buffer, in volume percentage include 10%-50% phosphate buffer, 50%-90% purified water; or the components of the buffer, in volume percentage, include 20%-40 % phosphate buffer, 60%-80% purified water.
  • the concentration of phosphate is 0.02M (mol/liter) to 0.1M (mol/liter).
  • the phosphate concentration in the pretreatment reagent is from 0.02M (mol/liter) to 0.1M (mol/liter) after being prepared as a pretreatment reagent, so as to ensure the concentration of the pretreatment reagent.
  • the pretreatment effect can not only maintain the cell shape, but also increase the permeability of the cell membrane, so that the uniformity of subsequent staining can be improved.
  • the components of the phosphate buffer include 5.3%-73.5% dihydrogen phosphate solution and 26.5%-94.7% hydrogen phosphate di-salt solution in volume percentage.
  • the pH of the phosphate buffer is 6.4-8.0.
  • the components of the phosphate buffer include, by volume percentage, 13%-51% dihydrogen phosphate solution and 49%-87% hydrogen phosphate di-salt solution; the pH value of the phosphate buffer is 6.8.-7.6.
  • the composition of the phosphate buffer solution includes 28% dihydrogen phosphate solution and 72% dihydrogen phosphate solution in volume percentage.
  • the concentration of dihydrogen phosphate in the dihydrogen phosphate solution is 0.2M (mol/liter); the concentration of dihydrogen phosphate in the dihydrogen phosphate solution is 0.2M (mol/liter).
  • the technical solution of the present application to solve the above problems can also be a preparation method of pretreatment reagent, which is used to prepare the pretreatment reagent, including the following steps, step D: take glutaraldehyde solution and aldehyde solution with 33.3%: 66.7 % to 50%:50% volume ratio to prepare a stabilizer; Step E: Mix the stabilizer and buffer solution prepared in step D with a volume ratio of 0.5:99.5 to 5:95 to prepare a pretreatment reagent.
  • the preparation method of the pretreatment reagent also includes the following steps before step D: Step A: the step of preparing a 0.2M (mol/liter) dihydrogen phosphate solution; weigh the quantitative anhydrous dihydrogen phosphate, dissolve in the corresponding 0.2M (mol/liter) dihydrogen phosphate solution in 0.2M (mol/liter) dihydrogen phosphate solution; step B: the step of preparing 0.2M (mol/liter) dihydrogen phosphate solution; weigh quantitative anhydrous dihydrogen phosphate , be dissolved in the purified water of corresponding volume, and constant volume makes 0.2M (mol/liter) dihydrogen phosphate solution;
  • the solution is mixed and prepared into a phosphate buffer solution with a pH value of 6.4-8.0;
  • the buffer solution used in step E is the phosphate buffer solution obtained in step C;
  • the salt concentration range is 0.02M (mol/liter) to 0.1M (mol/liter); the pH value range of the pretreatment reagent is 6.5-8.1.
  • the technical solution of the present application to solve the above problems can also be a pretreatment method, a pretreatment method, which uses the above-mentioned pretreatment reagent to pretreat the sample to be stained before cell staining; including the following steps: Step 1: the sample to be stained Mix evenly with the pretreatment reagent at a volume ratio of 1:49 to 1:399 to complete the pretreatment of the sample to be stained.
  • the technical solution of the present application to solve the above problems can also be a cell staining method for staining cells in a suspension; the above-mentioned pretreatment method is used to pretreat the sample to be stained before adding the staining solution.
  • the staining solution added to the suspension includes: Regis staining solution, Wright staining solution, Giemsa staining solution, new methylene blue staining solution, brilliant tar blue staining solution, Diff rapid staining solution any one or more of them.
  • the beneficial effects of the present application are: 1.
  • the cells in the sample to be stained, especially the blood cells in the blood sample, can be pretreated by the pretreatment reagent, and the structure of the blood cells can be preserved intact, and can be more truly Preserve the real structural information of its clinical state; 2.
  • the pretreatment method after being used with the staining solution, the state of the red blood cells and white blood cells in the blood cells after staining is relatively balanced, and can reach Uniform color degree is convenient for follow-up observation; 3.
  • the sample suspension to be treated after the above pretreatment reagent the cell staining time is shortened to 1 minute to 3 minutes, and the staining efficiency is greatly improved; 4.
  • the preparation method of the pretreatment reagent for staining It is simple, and the components are also very easy to obtain; it is a very convenient and efficient dyeing pretreatment solution; 5.
  • the cell staining operation is simple, and the fool-like staining operation can be realized, making it suitable for various application scenarios .
  • Fig. 1 is a schematic flow diagram of the preparation method of the pretreatment reagent and the pretreatment method and the cell staining method of the sample to be stained with the pretreatment reagent;
  • Fig. 2 to Fig. 4 are respectively the micrographs obtained after tiling of the stained cell suspension obtained after the pretreatment reagent treatment in the embodiment 1 to the embodiment 3 after staining;
  • Figure 2 Staining effect diagrams under different cell densities, the volume ratio of the sample to the pretreatment reagent is 1:149, the number of cells in the field of view is moderate, evenly distributed, and the staining is transparent;
  • Figure 3 The staining effect diagrams under different cell densities, the sample and The volume ratio of the pretreatment reagent is 1:49, the number of cells is large, the arrangement is tight, and the staining information of platelets is easily blocked;
  • Figure 4 shows the staining effect under different cell densities, the volume ratio of the sample to the pretreatment reagent is 1:399, the cells The number is small, the distribution is sparse, and the staining effect is average;
  • Figure 2, Figure 3, and Figure 4 are the renderings of staining at different densities for 4 minutes. All three ratios can obtain good cell distribution staining effects, and the effect in Figure 2 is the best .
  • Fig. 5 to Fig. 7 are the micrographs obtained after the stained cell suspension obtained after staining after the pretreatment reagent treatment in the embodiment 4 to the embodiment 6 respectively;
  • Fig. 5 staining under different stabilizer concentrations Effect picture the volume ratio of stabilizer and buffer solution is 1.75:98.25, the cells are clearly differentiated after staining;
  • Figure 6 The staining effect picture under different concentrations of stabilizer, the volume ratio of stabilizer and buffer solution is 5:95, the cells after staining The degree of differentiation is not obvious, and the nuclei of white blood cells are lightly stained;
  • Figure 7 shows the staining effect under different concentrations of stabilizers.
  • Figure 5 Figure 6, and Figure 7 are a set of effect diagrams of staining for 4 minutes under different stabilizer concentrations, in which the volume ratio of the three stabilizers to the buffer can obtain better staining results, Among them, in Figure 5, the red blood cell structure is intact, the white blood cell nuclear staining structure is clear, and the red blood cell is clearly distinguished from the white blood cell and platelet, and its staining is the best.
  • Fig. 8 to Fig. 10 are respectively the micrographs of the stained cell suspension obtained after the staining obtained after the pretreatment reagent treatment in the embodiment 7 to the embodiment 9;
  • Fig. 11 to Fig. 13 are the micrographs obtained after tiling of the stained cell suspension obtained after the pretreatment reagent treatment in embodiment 10 to embodiment 12 after staining;
  • Fig. 11 pH value of different pretreatment reagents The following staining effect diagram, when the pH value of the pretreatment reagent is 7.2, the cell structure is intact, and the differentiation of different cells is good;
  • Figure 12 The staining effect diagram under different pH values of the pretreatment reagent, when the pH value of the pretreatment reagent is 8.0, the cell staining is too deep , the shape of the white blood cell nucleus cannot be distinguished;
  • Figure 13 is the staining effect of different pretreatment reagent pH values.
  • the staining effect is better when the pH value is from 6.4 to 8.0, and the staining effect of red blood cell morphology and white blood cell in Figure 11 is better.
  • Fig. 14 to Fig. 16 are the micrographs obtained after the stained cell suspension obtained after staining after the pretreatment reagent treatment in the embodiment 13 to the embodiment 15 respectively;
  • Fig. 14 replaces the stabilizer with methanol formaldehyde, the volume ratio of methanol in the stabilizer is 80%;
  • Figure 15 replaces the formaldehyde in the stabilizer with methanol, and the volume ratio of methanol in the stabilizer is 57.1%;
  • Figure 16 replaces the formaldehyde in the stabilizer with methanol , the volume ratio of methanol in the stabilizer is 88.9%;
  • Figure 14, Figure 15, and Figure 16 methanol in different volume proportions is used to replace the formaldehyde in the stabilizer, and the dyeing effect of this system is better in 4 minutes, in which Figure 14 The neutrophils were uniformly stained, the nuclear outline was clear, and the red blood cells were in complete shape.
  • Methanol includes anhydrous methanol, or methanol solutions of other concentrations that
  • Fig. 17 to Fig. 19 are the micrographs obtained after tiling of the stained cell suspension obtained after staining after the pretreatment reagent treatment in the embodiment 16 to the embodiment 18 respectively;
  • Fig. 17 replaces the stabilizer with ethanol formaldehyde, the volume ratio of ethanol in the stabilizer is 80%;
  • Figure 18 replaces the formaldehyde in the stabilizer with ethanol, and the volume ratio of ethanol in the stabilizer is 57.1%;
  • Figure 19 replaces the formaldehyde in the stabilizer with ethanol , the volume ratio of ethanol in the stabilizer is 88.9%;
  • Figure 17, Figure 18, and Figure 19 the formaldehyde in the stabilizer is replaced by ethanol with different volume ratios, and the dyeing effect of the system is better in 4 minutes, among which Figure 17
  • the neutrophils were uniformly stained, the nuclear outline was clear, and the red blood cells were in complete shape.
  • Ethanol includes absolute ethanol, or ethanol solutions of other concentrations that achieve the same
  • the microscopic magnification of the above micrographs is 400 times; in the above micrographs, the cells are suspended in the suspension with a "three-dimensional" structure, and the positions of different cells in the suspension are different, and different cells will be in different positions.
  • the focus plane of microscopic imaging; and the focus area of the microscope to the field of view is usually selected in the middle of the field of view, and the edge of the field of view will have virtual focus due to spherical aberration, aberration, etc., so the cell images in the edge of some pictures are slightly blurred.
  • Fig. 1 is a schematic flowchart of the preparation method of the pretreatment reagent, the pretreatment method of the sample to be stained with the pretreatment reagent and the cell staining method.
  • Step 1 Prepare 0.2M sodium dihydrogen phosphate solution: weigh 23.99 g of anhydrous sodium dihydrogen phosphate, dissolve it in 800 ml of purified water, and dilute to 1000 ml;
  • Step 2 Prepare 0.2M disodium hydrogen phosphate solution; weigh 28.39 grams of anhydrous disodium hydrogen phosphate, dissolve in 800 ml of purified water, and dilute to 1000 ml;
  • Step 3 Prepare the optimal 0.2M phosphate buffer system; mix 0.2M sodium dihydrogen phosphate solution and 0.2M disodium hydrogen phosphate solution in a volume ratio of 28:72, and the pH value of the 0.2M phosphate buffer solution is 7.2;
  • Step 4 Mix the phosphate buffer solution in step: 3 with purified water in a volume ratio of 3:7 to prepare a buffer solution;
  • Step 5 Take 50% glutaraldehyde and 37% formaldehyde and mix them according to the volume ratio of 7.5:10 to make a stabilizer;
  • Step 6 Mix the phosphate buffer obtained in step 4 with the stabilizer obtained in step 5 according to the volume ratio of 1.75:98.25, and configure it as a pretreatment reagent; the phosphate concentration in the pretreatment reagent is 0.06M (mol/liter ); the pH value of the pretreatment reagent is 7.3;
  • Step 8 Add an appropriate proportion of commercial Regis staining solution to the mixture prepared in step 7, mix well, and take pictures under a microscope.
  • Example 1 to Example 3 the sample and the sample processing reagent were mixed according to the ratio of 1:49, 1:149 and 1:399 respectively, and then commercialized Regis staining solution was added to carry out the staining test;
  • Example 2 is taken as an example, the volume ratio of sample and sample treatment solution is 1:149; the operation is as follows, take 0.005ml of fresh blood sample, add it to 0.745ml of sample treatment reagent, mix and react for 1 minute; then add 10ul commercial Thinned Rigi's staining solution, mixed evenly and then microscopically examined and photographed.
  • Fig. 2 is the micrograph obtained after the stained cell suspension obtained after staining with the pretreatment reagent of Example 1;
  • Fig. 3 is stained with the pretreatment reagent of Example 2 The micrograph obtained after the stained cell suspension obtained after tiling;
  • Fig. 4 is the micrograph obtained after the stained cell suspension obtained after staining with the pretreatment reagent of Example 3 picture.
  • embodiment 4 to embodiment 6 can show the influence of different stabilizing agent contents on sample pretreatment;
  • Figures 5 to 7 are micrographs of the stained cell suspensions obtained after the staining was performed after the pretreatment reagents in Examples 4 to 6 were tiled.
  • pretreatment reagent preparation of embodiment 7 to embodiment 9 comprise the following steps:
  • Step 1 Mix 0.2M dihydrogen phosphate solution and 0.2M dihydrogen phosphate solution in a volume ratio of 28:72 to prepare a phosphate buffer solution with a pH value equal to 7.2 and a concentration of 0.2M (mol/liter);
  • Step 2 Dilute 0.2M phosphate buffer solution and purified water into phosphate buffer solution according to the volume ratio of 1:9, 5:5, and 3:7 respectively;
  • Step 3 Dilute 50% glutaraldehyde solution in the stabilizer with 37% formaldehyde solution is mixed according to the volume ratio equal to 42.9:57.1 to obtain the stabilizer;
  • Step 4 Add the stabilizer to the above phosphate buffer respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, before preparing Treatment reagent, at this time the phosphate concentration in the pre-treatment reagent is 0.02M, 0.1M and 0.06M respectively; pH is 7.2;
  • Step 5 Take 0.005ml of fresh blood sample, add it to
  • Example 10 to 12 the influence of different pH environments on sample pretreatment can be seen; in Examples 10 to 12, the "0.2M phosphate buffer system" is prepared first.
  • Step 1 First prepare 0.2M sodium dihydrogen phosphate solution: weigh 23.99 grams of anhydrous sodium dihydrogen phosphate, dissolve it in 800 ml of purified water, and set the volume to 1000 ml;
  • Step 2 Prepare a 0.2M disodium hydrogen phosphate solution; weigh 28.39 g of anhydrous disodium phosphate, dissolve it in 800 ml of purified water, and dilute to 1000 ml.
  • Step 3 Prepare the optimal 0.2M phosphate buffer solution; in Example 10, mix 0.2M sodium dihydrogen phosphate solution with 0.2M disodium hydrogen phosphate solution in a volume ratio of 28:72, then 0.2M phosphate buffer The pH value of the solution is 7.2; in Example 11, the 0.2M general range upper limit phosphate buffer system was prepared by mixing 0.2M sodium dihydrogen phosphate solution and 0.2M disodium hydrogen phosphate solution according to the volume ratio of 5.3:94.7.
  • Step 4 Mix the above three 0.2M phosphate buffers with purified water in a volume ratio of 3:7 to prepare three buffers with different pH values;
  • Step 5 Mix 50% glutaraldehyde solution and 37% formaldehyde solution in the stabilizer according to the volume ratio equal to 42.9:57.1 to obtain the stabilizer;
  • Step 6 Add the stabilizer to the above-mentioned phosphate buffer with pH values of 7.2, 8.0, and 6.4 respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, and prepare the pretreatment reagents of Examples 10 to 12 respectively ; Now the phosphate concentration in the pretreatment reagent is 0.06M, and the pH value of the pretreatment reagent is 7.3, 8.1, 6.5 respectively;
  • Step 7 Take another 0.005ml fresh blood sample, add it to 0.495ml sample processing reagent, mix well and react for 1 minute;
  • Step 8 Add 10ul of commercial Regis staining solution, mix well and take pictures under microscope.
  • Figures 11 to 13 are micrographs of the stained cell suspensions obtained after being stained after being treated with the pretreatment reagents in Examples 10 to 12, respectively.
  • Step 1 Mix 0.2M dihydrogen phosphate solution and 0.2M dihydrogen phosphate solution in a volume ratio of 28:72 to prepare a phosphate buffer solution with a pH value equal to 7.2 and a concentration of 0.2M (mol/liter);
  • Step 2 Dilute 0.2M phosphate buffer solution and purified water into phosphate buffer solution at a volume ratio of 3:7;
  • Step 3 Mix 50% glutaraldehyde solution and anhydrous methanol solution in the stabilizer according to volume ratios equal to 20%: 80%, 42.9%: 57.1%, 11.1%: 88.9%, respectively, to obtain the stabilizer;
  • Step 4 Add the stabilizer to the above-mentioned phosphate buffer respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, and prepare the pretreatment reagent; at this time, the phosphate concentration in the pretreatment reagent is 0.02M, 0.1M M and 0.06M, the pH value of the pretreatment reagent is 7.2; take 0.005ml fresh blood sample, add it to 0.495ml sample treatment reagent, mix and react for 1 minute; then add 10ul of commercial Regis staining solution, mix After uniformity, take pictures under the microscope.
  • Figures 14 to 16 are micrographs of the stained cell suspensions obtained after the staining was performed after the pretreatment reagents in Examples 13 to 15 were tiled.
  • embodiment 16 to embodiment 18 in the pretreatment reagent preparation and pretreatment method and dyeing method comprise the following steps:
  • Step 1 Mix 0.2M dihydrogen phosphate solution and 0.2M dihydrogen phosphate solution in a volume ratio of 28:72 to prepare a phosphate buffer solution with a pH value equal to 7.2 and a concentration of 0.2M (mol/liter);
  • Step 2 Dilute 0.2M phosphate buffer solution and purified water into phosphate buffer solution at a volume ratio of 3:7;
  • Step 3 Mix 50% glutaraldehyde solution and absolute ethanol solution in the stabilizer according to volume ratios equal to 20%: 80%, 42.9%: 57.1%, 11.1%: 88.9%, respectively, to obtain the stabilizer;
  • Step 4 Add the stabilizer to the above-mentioned phosphate buffer respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, and it is prepared into the pretreatment reagents of Examples 16 to 18. At this time, the phosphate concentration in the pretreatment reagent Both are 0.06M, and the pH value is 7.3;
  • Step 5 Take 0.005ml of fresh blood sample, add it to 0.495ml of sample processing reagent, mix well and react for 1 minute; then add 10ul of commercial Regis staining solution, mix well and take pictures under microscope.
  • Figures 17 to 19 are micrographs of the stained cell suspensions obtained after the staining was performed after the pretreatment reagents in Examples 16 to 18 were tiled.
  • the technical effects include multiple aspects.
  • the pretreatment of the present application can cross-link the membrane protein on the surface of the cell membrane to form a network structure on the surface of the cell membrane to maintain the cell shape, while destroying the phospholipid bilayer of the cell membrane and increasing the permeability of the cell membrane;
  • After treatment on the one hand, it can maintain a good cell shape, and at the same time, by maintaining the cell shape, it also maintains the activity of the internal substances in the cell, so that the internal environment inside the cell is closer to the original physiological environment of the cell, and the time for maintaining the activity of the organelles inside the cell will be longer. longer.
  • the staining solution enters the cell, it can exert the activity of the internal organelles of the cell and achieve the purpose of rapidly staining the cell.
  • the cell staining reagent and staining method designed in the present application can complete cell staining in body fluid or secretion in liquid suspension. Its applicable samples include various biological fluids such as blood, secretions such as urine or leucorrhea, etc.
  • the cells in the sample to be stained complete the staining process in a liquid suspension, and the environment used for the staining solution and diluent is relatively close to the biological physiological state, so in the staining process, the cell activity
  • it can use the Brownian motion of the cells and the dye molecules in the solution and the electrostatic force to carry out the dyeing reaction, and the dyeing speed is faster and the efficiency is higher; on the other hand, due to such a dyeing environment,
  • the cell viability is kept relatively well, and fast and balanced cell staining can be achieved through the pre-treated samples to be stained. It is especially suitable for the pre-treatment of live cell staining, which can greatly improve the efficiency of cell staining.
  • the ratio between the sample staining reagent and the sample is set reasonably, and the living cells in the sample can be stained.
  • the operation is simple, the staining is fast, the staining effect is better, and the staining result is more conducive to the shape of the cells.
  • the stained solution can be directly applied to the analysis and detection of cell morphology under bright field, and can further carry out cell classification and cell classification counting according to the analysis of the stained cell morphology and graphic characteristics.
  • cells are in a solution state to carry out live dyeing of blood samples in vitro, that is, using compound dyes with chromophores to directly stain blood cells, and based on blood cells under a bright field microscope
  • the cell characteristics presented in the staining results were analyzed for cell classification.
  • the body fluids or secretions stained by the method of the present application show cell characteristics including the size, color, shape, shape and color of the nucleus, the color of the cytoplasm, the color and the number of particles in the cytoplasm.
  • the stained sample in this application is suitable for morphological analysis of cells, based on the analysis of cell characteristics such as cell morphology and coloring degree of staining, cell classification, identification and counting can be performed.
  • the main feature of the present application is that the state of the sample cells is in a physiological or close to physiological state when staining in the present application.
  • the main feature of this application is that the reaction environment during dyeing is completely different from the operation, and this application does not involve the process of drying and cleaning; in this application, the cells in the sample Always in a liquid solution environment, after pretreatment with the sample of pretreatment reagents, various target cells to be stained have more balanced staining characteristics, and the staining reaction is carried out, the staining efficiency is higher, and the staining efficiency of different cells is more balanced.
  • the above reagents and methods can perform efficient pretreatment and efficient staining of the active cells in the sample, have low requirements on the operator, uniform staining, and short time-consuming, and can realize a serious staining process; avoiding the need for cells in the prior art
  • the dyeing operation is cumbersome, the professional requirements are high, the time is long, the dyeing is easy to be uneven, and the dyeing material cost is high.
  • the pretreatment and dyeing operations are simple, and can realize fool-like dyeing operations, making it suitable for various application scenarios. Scenarios such as instant inspection are also applicable to various application scenarios that lack large-scale professional equipment, professionals, and complex inspection environments, such as first aid, bedside, and battlefield.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed is a pretreatment reagent. The pretreatment reagent is used for the pretreatment of a cell stain in suspension, and the components thereof comprise, in percentages by volume, 0.5-5% of a stabilizer and 95-99.5% of a buffer. The components of the stabilizer comprise, in percentages by volume, 33.3-50% of a glutaraldehyde solution and 50-66.7% of a formaldehyde solution; and the pH value range of the pretreatment reagent is 6.5-8.1. On the one hand, the stabilizer enables the membrane protein on the surface of the cell membrane to be crosslinked, so that a reticular structure is formed on the surface of the cell membrane, and the cell morphology is maintained; on the other hand, the phospholipid bilayer of the cell membrane is destroyed, the permeability of the cell membrane is increased, and the efficiency of entering the cell of the subsequent dye is consistent and rapid, such that the cell staining time is shortened, the dyeing uniformity becomes high, and the reagent can be applied to various application scenarios.

Description

前处理试剂及制备方法和细胞染色方法及前处理方法Pretreatment reagent and preparation method, cell staining method and pretreatment method 技术领域technical field
本申请属于细胞染色技术领域,尤其涉及在悬浮液状态下的细胞染色技术,尤其涉及悬浮液状态下的细胞染色前处理的方法及试剂。The present application belongs to the technical field of cell staining, and in particular relates to the cell staining technology in the state of suspension, especially to the method and reagents for pre-treatment of cell staining in the state of suspension.
背景技术Background technique
在生物体体液或分泌物的细胞检测中,通常采用细胞染色技术来区分不同种类、不同形态、不同状态的细胞。In the cell detection of biological fluids or secretions, cell staining techniques are usually used to distinguish cells of different types, shapes, and states.
用于明场观察检测的常规细胞染色技术中,通常是将待检测样本涂抹在透明载体如载玻片上,等检测样本干燥后,再依次滴入具有不同染色效果的染液及缓冲液,混合均匀完成染色后,再冲洗掉影响观测的染液及缓冲液主体,再等待染色样本干燥后,完成整个染色过程,形成用于明场观测的染色后的样本涂片。现有技术中的干片染色步骤极其繁琐耗时,染色效率极低,无法大批量进行样本细胞染色。且每个步骤的操作都需训练有素的专业操作者,才能制作出合格的观测样本。且干片染色需要的时间较长,效率较低,在大批量样本检测时候成本效率都不能满足现实的需求。In the conventional cell staining technology for bright field observation and detection, the sample to be tested is usually smeared on a transparent carrier such as a glass slide. After the dyeing is evenly completed, the main body of the dye solution and buffer solution that affect the observation is washed away, and the dyed sample is dried after waiting for the entire dyeing process to form a stained sample smear for bright field observation. The dry film staining steps in the prior art are extremely cumbersome and time-consuming, and the staining efficiency is extremely low, making it impossible to stain sample cells in large quantities. And the operation of each step requires well-trained professional operators in order to produce qualified observation samples. In addition, it takes a long time to dye the dry film and the efficiency is low, and the cost efficiency cannot meet the actual needs when testing a large number of samples.
血细胞在液体环境即在悬浮液中染色时,无需干片制作的复杂过程;但是在悬浮液中进行染色时,染色液中的盐环境、或有机溶剂、表面活性剂的存在,往往会使血细胞形态的剧烈变化,如皱缩、破裂等。最终导致血液细胞液体在上述环境下染色后,无法输出完整的临床信息:如细胞的数量信息、形态信息、分类信息等。且染色的效果由于在悬浮液中容易受到各种组分的影响,要么难以染色,要么染色着色的需要时间较长;且对不同的细胞,很难在较为均衡的时间窗口达到同等水平的染色效果。When blood cells are stained in a liquid environment, that is, in suspension, there is no need for the complicated process of making dry films; but when staining in suspension, the presence of salt environment, organic solvents, or surfactants in the staining solution often makes blood cells Dramatic changes in shape, such as shrinkage, rupture, etc. Ultimately, after the blood cell liquid is stained in the above environment, it is impossible to output complete clinical information: such as cell quantity information, morphological information, classification information, etc. And the staining effect is easily affected by various components in the suspension, either it is difficult to stain, or it takes a long time for staining; and for different cells, it is difficult to achieve the same level of staining in a more balanced time window Effect.
名词解释:Glossary:
CAS编号(CASRegistryNumber或称CASNumber,CASRn,CAS#),又称CAS登录号或CAS登记号码,是某种物质(化合物、高分子材料、生物序列(Biologicalsequences)、混合物或合金)的唯一的数字识别号码。其由美国化学会的下设组织化学文摘社(ChemicalAbstractsService,简称CAS)构建。该社负责为每一种出现在文献中的物质分配一个CAS编号,避免了化学物质有多种名称的麻烦,使数据库的检索更为方便。CAS number (CASRegistryNumber or CASNumber, CASRn, CAS#), also known as CAS registration number or CAS registration number, is the unique digital identification of a certain substance (compound, polymer material, biological sequence (Biological sequences), mixture or alloy) Number. It is constructed by the Chemical Abstracts Service (CAS) under the American Chemical Society. The agency is responsible for assigning a CAS number to each substance that appears in the literature, which avoids the trouble of having multiple names for chemical substances and makes the database search more convenient.
纯化水是指符合《中国药典(2015版)》纯化水标准的水,其主要参数为:pH值为4.4-7.6之间,使用离线电导率仪检测,25℃温度下,标示装量不大于10ml(毫升)时,电导率不大于25μS/cm(微西门子每厘米)的水。Purified water refers to the water that meets the purified water standard of "Chinese Pharmacopoeia (2015 Edition)". Its main parameters are: the pH value is between 4.4 and 7.6, and the off-line conductivity meter is used to detect it. Water with a conductivity not greater than 25 μS/cm (micro Siemens per centimeter) at 10 ml (milliliter).
瑞吉氏染色液是指,以伊红、美兰、天青为主要染色物质,经过一定的加工工艺,形成的液态染色液。如珠海贝索生物技术有限公司的姬姆萨染色液(货号BA-4017)。Regis staining solution refers to the liquid dyeing solution formed by using eosin, methylene blue and azure as the main dyeing substances after certain processing technology. For example, Giemsa staining solution (Product No. BA-4017) from Zhuhai Beisuo Biotechnology Co., Ltd.
瑞氏(Wright)染色液是指:以伊红和美蓝为主要染料,经一定有机溶剂溶解、混合、经化学作用后,形成的染色液。如北京索莱宝科技有限公司的瑞氏染色液(货号G1040)Wright's staining solution refers to the dyeing solution formed by using eosin and methylene blue as the main dyes, dissolving, mixing, and chemically acting in a certain organic solvent. For example, Wright's staining solution (article number G1040) of Beijing Suolaibao Technology Co., Ltd.
吉姆萨(Giemsa)染色液是指:以酸性伊红和天青为主要染料,经一定有机溶剂溶解、混合、经化学作用后,形成的染色液。如珠海贝索生物技术有限公司的姬姆萨染色液(货号BA-4219)。Giemsa dyeing solution refers to the dyeing solution formed after the main dyes are acid eosin and azure, which are dissolved, mixed and chemically reacted by certain organic solvents. For example, Giemsa staining solution (Product No. BA-4219) from Zhuhai Beisuo Biotechnology Co., Ltd.
新亚甲蓝染色液是指:以新亚甲蓝作为主要染料,通过一定的有机或无机溶剂溶解后,形成的染色液。如珠海贝索生物技术有限公司的姬姆萨染色液(货号BA-4003)。New methylene blue dyeing solution refers to the dyeing solution formed by using new methylene blue as the main dye and dissolving it in a certain organic or inorganic solvent. For example, Giemsa staining solution (Product No. BA-4003) from Zhuhai Beisuo Biotechnology Co., Ltd.
煌焦油蓝染色液是指:以灿烂甲酚蓝为主要染料,通过一定的有机或无机溶剂溶解后,形成的染色液。如北京索莱宝科技有限公司的瑞氏染色液(货号G1410)。Brilliant tar blue dyeing solution refers to a dyeing solution formed by dissolving brilliant cresyl blue as the main dye in a certain organic or inorganic solvent. Such as Wright's staining solution (product number G1410) of Beijing Soleibao Technology Co., Ltd.
迪夫染色液是指,以水溶性伊红和美兰、天青Ⅱ,为主要染料,以水为主要溶剂,经一定工艺形成的染色液。如北京索莱宝科技有限公司的瑞氏染色液(货号G1541)。Diff's dyeing solution refers to the dyeing solution formed by a certain process with water-soluble eosin, melanin and azure II as the main dyes and water as the main solvent. For example, Wright's staining solution (product number G1541) of Beijing Suo Laibao Technology Co., Ltd.
技术问题technical problem
本申请要解决的技术问题在于避免现有技术上述不足之处,提出了一种简单高效的前处理试剂及制备方法和细胞染色方法及前处理方法,在细胞在进入悬浮液中染色之前先进行前处理,使细胞状态调整为适合进行悬浮液染色的状态,非常适用于规模化批量化的样本细胞染色。The technical problem to be solved in this application is to avoid the above-mentioned shortcomings of the prior art, and propose a simple and efficient pretreatment reagent and preparation method, a cell staining method and a pretreatment method. The pre-treatment adjusts the cell state to a state suitable for suspension staining, which is very suitable for large-scale and batch sample cell staining.
技术解决方案technical solution
本申请解决上述问题的技术方案是一种前处理试剂用于细胞在悬浮液中染色的前处理,其组分,以体积百分比计,包括0.5%-5%稳定剂,95%-99.5%缓冲液。The technical scheme of the present application to solve the above-mentioned problems is a pretreatment reagent used for pretreatment of cells stained in suspension, and its components, by volume percentage, include 0.5%-5% stabilizer, 95%-99.5% buffer liquid.
本方案中的稳定剂,一方面使细胞膜表面膜蛋白发生交联,使在细胞膜表面形成网状结构,保持细胞形态;另一方面破坏细胞膜的磷脂双分子层,增加细胞膜的透过性,使后续染料进入细胞的效率一致,且快速;使细胞染色的时间变短,染色均一性变高。The stabilizer in this solution, on the one hand, cross-links the membrane proteins on the cell membrane surface to form a network structure on the cell membrane surface to maintain the cell shape; on the other hand, it destroys the phospholipid bilayer of the cell membrane and increases the permeability of the cell membrane. The efficiency of subsequent dyes entering the cells is consistent and fast; the time for cell staining is shortened, and the uniformity of staining becomes higher.
所述的前处理试剂其组分,以体积百分比计,包括1%-3%稳定剂,97%-99%缓冲液。优选地,前处理试剂其组分,以体积百分比计,包括1.75%稳定剂,98.25%缓冲液。The components of the pretreatment reagent include 1%-3% stabilizer and 97%-99% buffer in volume percentage. Preferably, the components of the pretreatment reagent include 1.75% stabilizer and 98.25% buffer in volume percentage.
所述前处理试剂的pH值范围为6.5-8.1;或所述前处理试剂的pH值范围为6.8-7.6。The pH value range of the pretreatment reagent is 6.5-8.1; or the pH value range of the pretreatment reagent is 6.8-7.6.
所述稳定剂的组分,以体积百分比计,包括33.3%-50%戊二醛溶液,50%-66.7%醛类溶液;或所述稳定剂的组分,以体积百分比计,包括40%-50%戊二醛溶液,50%-60%醛类溶液。The components of the stabilizer, by volume percentage, include 33.3%-50% glutaraldehyde solution, 50%-66.7% aldehyde solution; or the components of the stabilizer, by volume percentage, include 40% -50% glutaraldehyde solution, 50%-60% aldehyde solution.
优选地,所述稳定剂的组分,以体积百分比计,包括42.9%戊二醛溶液和57.1%甲醛溶液。Preferably, the components of the stabilizer include, by volume percentage, 42.9% glutaraldehyde solution and 57.1% formaldehyde solution.
所述醛类溶液中的醛类物质包括甲醛、乙醛、丙醛、多聚甲醛中的任意一种或多种。The aldehyde substances in the aldehyde solution include any one or more of formaldehyde, acetaldehyde, propionaldehyde and paraformaldehyde.
所述稳定剂的组分,以体积百分比计,包括21.1%-48.3%戊二醛溶液,51.7%-88.9%醇类溶液。The components of the stabilizer include, by volume percentage, 21.1%-48.3% glutaraldehyde solution and 51.7%-88.9% alcohol solution.
所述醇类溶液中的醇类物质包括无水甲醇或无水乙醇。Alcohol substances in the alcohol solution include absolute methanol or absolute ethanol.
所述戊二醛溶液是戊二醛的质量百分比为50%的戊二醛溶液;所述醛类溶液是醛类物质的质量百分比为37%的醛类溶液。The glutaraldehyde solution is a glutaraldehyde solution with a mass percentage of glutaraldehyde of 50%; the aldehyde solution is an aldehyde solution with a mass percentage of aldehydes of 37%.
优选地,所述甲醛溶液是甲醛的质量百分比为37%的甲醛溶液。Preferably, the formaldehyde solution is a formaldehyde solution with a mass percent of formaldehyde of 37%.
所述缓冲液的组分,以体积百分比计,包括10%-50%磷酸缓冲液,50%-90%纯化水;或所述缓冲液的组分,以体积百分比计,包括20%-40%磷酸缓冲液,60%-80%纯化水。The components of the buffer, in volume percentage, include 10%-50% phosphate buffer, 50%-90% purified water; or the components of the buffer, in volume percentage, include 20%-40 % phosphate buffer, 60%-80% purified water.
所述前处理试剂中,磷酸盐浓度0.02M(摩尔/升)至0.1M(摩尔/升)。In the pretreatment reagent, the concentration of phosphate is 0.02M (mol/liter) to 0.1M (mol/liter).
无论磷酸缓冲液中的磷酸盐浓度如何,需要保证配制成前处理试剂后,在前处理试剂中磷酸盐浓度0.02M(摩尔/升)至0.1M(摩尔/升),以保证前处理试剂的前处理效果,既能保持细胞形态,又能增加细胞膜的透过性,使后续染色均一性能提高。Regardless of the phosphate concentration in the phosphate buffer, it is necessary to ensure that the phosphate concentration in the pretreatment reagent is from 0.02M (mol/liter) to 0.1M (mol/liter) after being prepared as a pretreatment reagent, so as to ensure the concentration of the pretreatment reagent. The pretreatment effect can not only maintain the cell shape, but also increase the permeability of the cell membrane, so that the uniformity of subsequent staining can be improved.
所述磷酸缓冲液的组分,以体积百分比计,包括5.3%-73.5%磷酸二氢盐溶液和26.5%-94.7%磷酸氢二盐溶液。磷酸缓冲液的pH值为6.4-8.0。The components of the phosphate buffer include 5.3%-73.5% dihydrogen phosphate solution and 26.5%-94.7% hydrogen phosphate di-salt solution in volume percentage. The pH of the phosphate buffer is 6.4-8.0.
所述磷酸缓冲液的组分,以体积百分比计,包括13%-51%磷酸二氢盐溶液和49%-87%磷酸氢二盐溶液;磷酸缓冲液的pH值为6.8.-7.6。The components of the phosphate buffer include, by volume percentage, 13%-51% dihydrogen phosphate solution and 49%-87% hydrogen phosphate di-salt solution; the pH value of the phosphate buffer is 6.8.-7.6.
优选地,所述磷酸缓冲液的组分,以体积百分比计,包括28%磷酸二氢盐溶液和72%磷酸氢二盐溶液。Preferably, the composition of the phosphate buffer solution includes 28% dihydrogen phosphate solution and 72% dihydrogen phosphate solution in volume percentage.
优选地,所述磷酸二氢盐溶液的磷酸二氢盐浓度是0.2M(摩尔/升);所述磷酸氢二盐溶液的磷酸氢二盐浓度是0.2M(摩尔/升)。Preferably, the concentration of dihydrogen phosphate in the dihydrogen phosphate solution is 0.2M (mol/liter); the concentration of dihydrogen phosphate in the dihydrogen phosphate solution is 0.2M (mol/liter).
本申请解决上述问题的技术方案还可以是一种前处理试剂制备方法,用于制备所述的前处理试剂,包括以下步骤,步骤D:取戊二醛溶液和醛类溶液以33.3%:66.7%至50%:50%的体积比进行混合,制得稳定剂;步骤E:将步骤D制得的稳定剂和缓冲液以0.5:99.5至5:95的体积比混合制得前处理试剂。The technical solution of the present application to solve the above problems can also be a preparation method of pretreatment reagent, which is used to prepare the pretreatment reagent, including the following steps, step D: take glutaraldehyde solution and aldehyde solution with 33.3%: 66.7 % to 50%:50% volume ratio to prepare a stabilizer; Step E: Mix the stabilizer and buffer solution prepared in step D with a volume ratio of 0.5:99.5 to 5:95 to prepare a pretreatment reagent.
所述的前处理试剂制备方法,在步骤D之前还包括以下步骤:步骤A:配制0.2M(摩尔/升)磷酸二氢盐溶液的步骤;称取定量无水磷酸二氢盐,溶于相应容积的纯化水中,定容制得0.2M(摩尔/升)磷酸二氢盐溶液;步骤B:配制0.2M(摩尔/升)磷酸氢二盐溶液的步骤;称取定量无水磷酸氢二盐,溶于相应容积的纯化水中,定容制得0.2M(摩尔/升)磷酸二氢盐溶液;步骤C:利用步骤A制得的磷酸二氢盐溶液和步骤B制得的磷酸氢二盐溶液混合配制成pH值为6.4-8.0的磷酸缓冲液;步骤E中所用的缓冲液是步骤C制得的磷酸缓冲液;磷酸缓冲液的用量配比,会使制得的前处理试剂中磷酸盐浓度范围是0.02M(摩尔/升)至0.1M(摩尔/升);前处理试剂pH值范围为6.5-8.1。上述步骤A和步骤B不分先后顺序。The preparation method of the pretreatment reagent also includes the following steps before step D: Step A: the step of preparing a 0.2M (mol/liter) dihydrogen phosphate solution; weigh the quantitative anhydrous dihydrogen phosphate, dissolve in the corresponding 0.2M (mol/liter) dihydrogen phosphate solution in 0.2M (mol/liter) dihydrogen phosphate solution; step B: the step of preparing 0.2M (mol/liter) dihydrogen phosphate solution; weigh quantitative anhydrous dihydrogen phosphate , be dissolved in the purified water of corresponding volume, and constant volume makes 0.2M (mol/liter) dihydrogen phosphate solution; The solution is mixed and prepared into a phosphate buffer solution with a pH value of 6.4-8.0; the buffer solution used in step E is the phosphate buffer solution obtained in step C; The salt concentration range is 0.02M (mol/liter) to 0.1M (mol/liter); the pH value range of the pretreatment reagent is 6.5-8.1. The above steps A and B are in no particular order.
本申请解决上述问题的技术方案还可以是前处理方法,一种前处理方法,使用了上述的前处理试剂对待染色样本进行细胞染色之前的前处理;包括以下步骤:步骤1:将待染色样本和前处理试剂以1:49至1:399的体积比混合均匀,完成待染色样本的前处理。The technical solution of the present application to solve the above problems can also be a pretreatment method, a pretreatment method, which uses the above-mentioned pretreatment reagent to pretreat the sample to be stained before cell staining; including the following steps: Step 1: the sample to be stained Mix evenly with the pretreatment reagent at a volume ratio of 1:49 to 1:399 to complete the pretreatment of the sample to be stained.
本申请解决上述问题的技术方案还可以是一种细胞染色方法,用于在悬浮液中对细胞进行染色;在加入染色液之前采用了上述的前处理方法对待染色样本进行了前处理。The technical solution of the present application to solve the above problems can also be a cell staining method for staining cells in a suspension; the above-mentioned pretreatment method is used to pretreat the sample to be stained before adding the staining solution.
所述的细胞染色方法,在悬浮液中加入的染色液包括:瑞吉氏染色液、瑞氏染色液、吉姆萨染色液、新亚甲蓝染色液、煌焦油蓝染色液、迪夫快速染色液中的任意一种或多种。In the cell staining method, the staining solution added to the suspension includes: Regis staining solution, Wright staining solution, Giemsa staining solution, new methylene blue staining solution, brilliant tar blue staining solution, Diff rapid staining solution any one or more of them.
有益效果Beneficial effect
同现有技术相比较,本申请的有益效果是:1.待染色样本中的细胞尤其是血液样品中的血细胞,经过前处理试剂的前处理,血液细胞的结构能保存完好,能更真实地保存其临床状态下的真实结构信息;2.经过前处理方法处置后的血细胞,在配合染色液使用后,血液细胞中的红细胞和白细胞的染色后的状态比较均衡,能在同一时间节点,达到统一的颜色度,方便进行后续的观测;3.上述前处理试剂处理后的待处理样本悬浮液,细胞染色时间缩短至1分钟-3分钟,染色效率大大提升;4.染色前处理试剂配制方法简单,组分也非常容易获得;是非常方便高效的染色前处理方案;5.经过这样的前处理过程,使细胞染色操作简单,能实现傻瓜式的染色操作,使其适用于多种应用场景。如即时检验、急救、床边,战地等多种缺乏专业人员、大型设备和复杂检验环境的条件下。Compared with the prior art, the beneficial effects of the present application are: 1. The cells in the sample to be stained, especially the blood cells in the blood sample, can be pretreated by the pretreatment reagent, and the structure of the blood cells can be preserved intact, and can be more truly Preserve the real structural information of its clinical state; 2. After the blood cells are treated with the pretreatment method, after being used with the staining solution, the state of the red blood cells and white blood cells in the blood cells after staining is relatively balanced, and can reach Uniform color degree is convenient for follow-up observation; 3. For the sample suspension to be treated after the above pretreatment reagent, the cell staining time is shortened to 1 minute to 3 minutes, and the staining efficiency is greatly improved; 4. The preparation method of the pretreatment reagent for staining It is simple, and the components are also very easy to obtain; it is a very convenient and efficient dyeing pretreatment solution; 5. After such a pretreatment process, the cell staining operation is simple, and the fool-like staining operation can be realized, making it suitable for various application scenarios . Such as immediate inspection, first aid, bedside, battlefield and other conditions that lack professionals, large equipment and complex inspection environments.
附图说明Description of drawings
图1是前处理试剂制备方法以及用前处理试剂对待染色样本进行前处理方法和细胞染色方法的流程示意图;Fig. 1 is a schematic flow diagram of the preparation method of the pretreatment reagent and the pretreatment method and the cell staining method of the sample to be stained with the pretreatment reagent;
图2至图4分别是实施例1至实施例3中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;Fig. 2 to Fig. 4 are respectively the micrographs obtained after tiling of the stained cell suspension obtained after the pretreatment reagent treatment in the embodiment 1 to the embodiment 3 after staining;
图2不同细胞密度下的染色效果图,样本与前处理试剂的体积比为1:149,视野下细胞数量适中,分布均匀,染色通透;图3不同细胞密度下的染色效果图,样本与前处理试剂的体积比为1:49,细胞数量大,排列紧密,易遮挡血小板的染色信息;图4不同细胞密度下的染色效果图,样本与前处理试剂的体积比为1:399,细胞数量小,分布稀疏,染色效果一般;图2、图3、图4为不同密度下的染色4分钟的效果图,三种比例均可得到好的细胞分布染色效果,其中图2的效果最佳。Figure 2 Staining effect diagrams under different cell densities, the volume ratio of the sample to the pretreatment reagent is 1:149, the number of cells in the field of view is moderate, evenly distributed, and the staining is transparent; Figure 3 The staining effect diagrams under different cell densities, the sample and The volume ratio of the pretreatment reagent is 1:49, the number of cells is large, the arrangement is tight, and the staining information of platelets is easily blocked; Figure 4 shows the staining effect under different cell densities, the volume ratio of the sample to the pretreatment reagent is 1:399, the cells The number is small, the distribution is sparse, and the staining effect is average; Figure 2, Figure 3, and Figure 4 are the renderings of staining at different densities for 4 minutes. All three ratios can obtain good cell distribution staining effects, and the effect in Figure 2 is the best .
图5至图7分别是实施例4至实施例6中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;图5不同稳定剂浓度下染色效果图,稳定剂与缓冲液的体积比为1.75:98.25,染色后细胞区分度明显;图6不同稳定剂浓度下染色效果图,稳定剂与缓冲液的体积比为5:95,染色后细胞区分度不明显,白细胞核浅染;图7不同稳定剂浓度下染色效果图,稳定剂与缓冲液的体积比为0.5:99.5,染色后细胞区分度不明显;红细胞大小有收缩,白细胞核与细胞质区分度稍差;图5、图6、图7为一组不同稳定剂浓度下的染色4分钟的效果图,其中三种稳定剂与缓冲液的体积比均可获得较好的染色效果,其中图5红细胞结构完好、白细胞核染色结构清晰,红细胞与白细胞、血小板区分明显,其染色最佳。Fig. 5 to Fig. 7 are the micrographs obtained after the stained cell suspension obtained after staining after the pretreatment reagent treatment in the embodiment 4 to the embodiment 6 respectively; Fig. 5 staining under different stabilizer concentrations Effect picture, the volume ratio of stabilizer and buffer solution is 1.75:98.25, the cells are clearly differentiated after staining; Figure 6 The staining effect picture under different concentrations of stabilizer, the volume ratio of stabilizer and buffer solution is 5:95, the cells after staining The degree of differentiation is not obvious, and the nuclei of white blood cells are lightly stained; Figure 7 shows the staining effect under different concentrations of stabilizers. The cytoplasmic discrimination is slightly poor; Figure 5, Figure 6, and Figure 7 are a set of effect diagrams of staining for 4 minutes under different stabilizer concentrations, in which the volume ratio of the three stabilizers to the buffer can obtain better staining results, Among them, in Figure 5, the red blood cell structure is intact, the white blood cell nuclear staining structure is clear, and the red blood cell is clearly distinguished from the white blood cell and platelet, and its staining is the best.
图8至图10分别是实施例7至实施例9中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;图8不同磷酸盐浓度的前处理试剂前处理后的下染色效果图,实施例7中,前处理试剂中磷酸盐浓度为0.06M(摩尔/L),如图8可见细胞结构完好,染色后细胞区分度明显;实施例8中,前处理试剂中磷酸盐浓度为0.1M(摩尔/L),如图9可见细胞结构完好,染色白细胞核与细胞质区分度一般;实施例8中前处理试剂中的磷酸盐浓度为0.02M(摩尔/L),如图10所示红细胞结构有形变,染色白细胞核与细胞质区分度尚可;图8、图9、图10为不同磷酸盐浓度的前处理试剂前处理后再染色4分钟的效果图,前处理试剂中的磷酸盐浓度从0.02M(摩尔/L)到0.1M(摩尔/L)条件,均可得到好的染色结果,其中图8红细胞、白细胞结构更完整,白细胞染色区分更明显,其条件最佳。Fig. 8 to Fig. 10 are respectively the micrographs of the stained cell suspension obtained after the staining obtained after the pretreatment reagent treatment in the embodiment 7 to the embodiment 9; The lower dyeing effect diagram after the pretreatment of the treatment reagent, in embodiment 7, the phosphate concentration in the pretreatment reagent is 0.06M (mol/L), as shown in Figure 8, the cell structure is intact, and the cell differentiation degree is obvious after staining; embodiment 8 Among them, the phosphate concentration in the pretreatment reagent is 0.1M (mol/L), as shown in Figure 9, the cell structure is intact, and the degree of differentiation between the stained leukocyte nucleus and the cytoplasm is general; the phosphate concentration in the pretreatment reagent in Example 8 is 0.02M (mol/L), as shown in Figure 10, the structure of red blood cells is deformed, and the degree of differentiation between the nucleus and cytoplasm of stained white blood cells is acceptable; Figure 8, Figure 9, and Figure 10 are pretreatment reagents with different phosphate concentrations and then stained for 4 minutes The effect diagram of the effect diagram, the phosphate concentration in the pretreatment reagent is from 0.02M (mol/L) to 0.1M (mol/L), and good staining results can be obtained, in which the structure of red blood cells and white blood cells is more complete in Figure 8, and the staining of white blood cells The distinction is more obvious and its condition is optimal.
图11至图13分别是实施例10至实施例12中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;图11不同前处理试剂pH值下染色效果图,前处理试剂pH值为7.2时,细胞结构完好,不同细胞区分度好;图12不同前处理试剂pH值下染色效果图,前处理试剂pH值为8.0时,细胞染色过深,白细胞核内形态无法分辨;图13不同前处理试剂pH值下染色效果图,前处理试剂pH值为6.4时,细胞浅染,且红细胞形态有胀大;图11、图12、图13为不同pH条件下的前处理试剂前处理后,再进行4分钟染色的染色效果图。pH值从6.4至8.0染色效果较好,其中图11的红细胞细胞形态与白细胞的染色效果更优。缓冲液的pH值和前处理试剂的PH值之间差异并不太大;缓冲液的PH值主导了前处理试剂的pH值。Fig. 11 to Fig. 13 are the micrographs obtained after tiling of the stained cell suspension obtained after the pretreatment reagent treatment in embodiment 10 to embodiment 12 after staining; Fig. 11 pH value of different pretreatment reagents The following staining effect diagram, when the pH value of the pretreatment reagent is 7.2, the cell structure is intact, and the differentiation of different cells is good; Figure 12 The staining effect diagram under different pH values of the pretreatment reagent, when the pH value of the pretreatment reagent is 8.0, the cell staining is too deep , the shape of the white blood cell nucleus cannot be distinguished; Figure 13 is the staining effect of different pretreatment reagent pH values. The dyeing effect diagram of 4 minutes of dyeing after pretreatment with pretreatment reagents under different pH conditions. The staining effect is better when the pH value is from 6.4 to 8.0, and the staining effect of red blood cell morphology and white blood cell in Figure 11 is better. There is not much difference between the pH of the buffer and the pH of the pretreatment reagent; the pH of the buffer dominates the pH of the pretreatment reagent.
图14至图16分别是实施例13至实施例15中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;图14用甲醇取代稳定剂中的甲醛,甲醇在稳定剂中的体积占比为80%;图15用甲醇取代稳定剂中的甲醛,甲醇在稳定剂中的体积占比为57.1%;图16用甲醇取代稳定剂中的甲醛,甲醇在稳定剂中的体积占比为88.9%;图14、图15、图16中,以不同体积占比的甲醇取代稳定剂中的甲醛,该体系4分钟染色效果较好,其中图14中白细胞染色均一、核轮廓清晰,红细胞形态完整。甲醇包括无水甲醇,或达等量无水甲醇相同效果的其他浓度的甲醇溶液也可以。Fig. 14 to Fig. 16 are the micrographs obtained after the stained cell suspension obtained after staining after the pretreatment reagent treatment in the embodiment 13 to the embodiment 15 respectively; Fig. 14 replaces the stabilizer with methanol formaldehyde, the volume ratio of methanol in the stabilizer is 80%; Figure 15 replaces the formaldehyde in the stabilizer with methanol, and the volume ratio of methanol in the stabilizer is 57.1%; Figure 16 replaces the formaldehyde in the stabilizer with methanol , the volume ratio of methanol in the stabilizer is 88.9%; in Figure 14, Figure 15, and Figure 16, methanol in different volume proportions is used to replace the formaldehyde in the stabilizer, and the dyeing effect of this system is better in 4 minutes, in which Figure 14 The neutrophils were uniformly stained, the nuclear outline was clear, and the red blood cells were in complete shape. Methanol includes anhydrous methanol, or methanol solutions of other concentrations that achieve the same effect as an equivalent amount of anhydrous methanol are also acceptable.
图17至图19分别是实施例16至实施例18中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;图17用乙醇取代稳定剂中的甲醛,乙醇在稳定剂中的体积占比为80%;图18用乙醇取代稳定剂中的甲醛,乙醇在稳定剂中的体积占比为57.1%;图19用乙醇取代稳定剂中的甲醛,乙醇在稳定剂中的体积占比为88.9%;图17、图18、图19中,以不同体积占比的乙醇取代稳定剂中的甲醛,该体系4分钟染色效果较好,其中图17中白细胞染色均一、核轮廓清晰,红细胞形态完整。乙醇包括无水乙醇,或达等量无水乙醇相同效果的其他浓度的乙醇溶液也可以。Fig. 17 to Fig. 19 are the micrographs obtained after tiling of the stained cell suspension obtained after staining after the pretreatment reagent treatment in the embodiment 16 to the embodiment 18 respectively; Fig. 17 replaces the stabilizer with ethanol formaldehyde, the volume ratio of ethanol in the stabilizer is 80%; Figure 18 replaces the formaldehyde in the stabilizer with ethanol, and the volume ratio of ethanol in the stabilizer is 57.1%; Figure 19 replaces the formaldehyde in the stabilizer with ethanol , the volume ratio of ethanol in the stabilizer is 88.9%; in Figure 17, Figure 18, and Figure 19, the formaldehyde in the stabilizer is replaced by ethanol with different volume ratios, and the dyeing effect of the system is better in 4 minutes, among which Figure 17 The neutrophils were uniformly stained, the nuclear outline was clear, and the red blood cells were in complete shape. Ethanol includes absolute ethanol, or ethanol solutions of other concentrations that achieve the same effect as an equivalent amount of absolute ethanol are also available.
上述显微图片的显微放大倍数均为400倍;上述显微照片中,细胞以“三维”结构在悬浮液中处于悬浮状态,不同细胞在悬浮液中的位置差异,不同细胞会处于不同的显微成像的对焦面上;且显微镜对视野的聚焦区域通常选择在视野中间区域,视野边缘因为球差、像差等原因会有虚焦,因此部分图片的边缘中的细胞影像略有模糊。The microscopic magnification of the above micrographs is 400 times; in the above micrographs, the cells are suspended in the suspension with a "three-dimensional" structure, and the positions of different cells in the suspension are different, and different cells will be in different positions. The focus plane of microscopic imaging; and the focus area of the microscope to the field of view is usually selected in the middle of the field of view, and the edge of the field of view will have virtual focus due to spherical aberration, aberration, etc., so the cell images in the edge of some pictures are slightly blurred.
本发明的实施方式Embodiments of the present invention
以下结合各附图对本申请的实施方式做进一步详述。Embodiments of the present application will be described in further detail below in conjunction with the accompanying drawings.
图1是前处理试剂制备方法以及用前处理试剂对待染色样本进行前处理方法和细胞染色方法的流程示意图。Fig. 1 is a schematic flowchart of the preparation method of the pretreatment reagent, the pretreatment method of the sample to be stained with the pretreatment reagent and the cell staining method.
如图1所示,包括以下步骤:As shown in Figure 1, the following steps are included:
步骤1:配制0.2M磷酸二氢钠溶液:称取23.99克无水磷酸二氢钠,溶于800毫升纯化水中,定容至1000毫升;Step 1: Prepare 0.2M sodium dihydrogen phosphate solution: weigh 23.99 g of anhydrous sodium dihydrogen phosphate, dissolve it in 800 ml of purified water, and dilute to 1000 ml;
步骤2:配制0.2M磷酸氢二钠溶液;称取28.39克无水磷氢二钠,溶于800毫升纯化水中,定容至1000毫升;Step 2: Prepare 0.2M disodium hydrogen phosphate solution; weigh 28.39 grams of anhydrous disodium hydrogen phosphate, dissolve in 800 ml of purified water, and dilute to 1000 ml;
步骤3:配制最佳0.2M磷酸缓冲液体系;将0.2M磷酸二氢钠溶液与0.2M磷酸氢二钠溶液按照28:72的体积比混合,此时0.2M磷酸缓冲液pH值为7.2;Step 3: Prepare the optimal 0.2M phosphate buffer system; mix 0.2M sodium dihydrogen phosphate solution and 0.2M disodium hydrogen phosphate solution in a volume ratio of 28:72, and the pH value of the 0.2M phosphate buffer solution is 7.2;
步骤4:把步骤:3的磷酸缓冲液与纯化水按照3:7的体积比混合,配制成缓冲液;Step 4: Mix the phosphate buffer solution in step: 3 with purified water in a volume ratio of 3:7 to prepare a buffer solution;
步骤5:取50%的戊二醛和37%的甲醛,按照7.5:10的体积比进行混合,配制成稳定剂;Step 5: Take 50% glutaraldehyde and 37% formaldehyde and mix them according to the volume ratio of 7.5:10 to make a stabilizer;
步骤6:将步骤4制得的磷酸缓冲液与步骤5获得的稳定剂按照体积比为1.75:98.25的比例混合,配置成前处理试剂;前处理试剂中磷酸盐浓度是0.06M(摩尔/升);前处理试剂pH值为7.3;Step 6: Mix the phosphate buffer obtained in step 4 with the stabilizer obtained in step 5 according to the volume ratio of 1.75:98.25, and configure it as a pretreatment reagent; the phosphate concentration in the pretreatment reagent is 0.06M (mol/liter ); the pH value of the pretreatment reagent is 7.3;
步骤7:取新鲜血液样本按照样本:前处理试剂=1:149的体积比进行混合,反应1分钟;Step 7: Take a fresh blood sample and mix it according to the volume ratio of sample: pretreatment reagent = 1:149, and react for 1 minute;
步骤8:在步骤7制得的混合液中加入合适比例的商品化瑞吉氏染色液,混匀,在显微镜下拍照。Step 8: Add an appropriate proportion of commercial Regis staining solution to the mixture prepared in step 7, mix well, and take pictures under a microscope.
在实施例1至实施例3中,将样本与样本处理试剂分别按1:49,1:149以及1:399的比例进行混合后,加入商品化的瑞吉氏染色液,进行染色试验;以实施例2为例,取样本和样本处理液的体积比为1:149;操作如下,取0.005ml新鲜血液样本,加入到0.745ml样本处理试剂中,混匀并反应1分钟;再加入10ul商品化的瑞吉氏染色液,混匀后镜检拍照。图2是用实施例1的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;图3是用实施例2的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片;图4是用实施例3的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片。In Example 1 to Example 3, the sample and the sample processing reagent were mixed according to the ratio of 1:49, 1:149 and 1:399 respectively, and then commercialized Regis staining solution was added to carry out the staining test; Example 2 is taken as an example, the volume ratio of sample and sample treatment solution is 1:149; the operation is as follows, take 0.005ml of fresh blood sample, add it to 0.745ml of sample treatment reagent, mix and react for 1 minute; then add 10ul commercial Thinned Rigi's staining solution, mixed evenly and then microscopically examined and photographed. Fig. 2 is the micrograph obtained after the stained cell suspension obtained after staining with the pretreatment reagent of Example 1; Fig. 3 is stained with the pretreatment reagent of Example 2 The micrograph obtained after the stained cell suspension obtained after tiling; Fig. 4 is the micrograph obtained after the stained cell suspension obtained after staining with the pretreatment reagent of Example 3 picture.
在实施例4至实施例6中,能显示不同的稳定剂含量,对样本前处理的影响;在实施例4至实施例6中,以50%戊二醛与37%甲醛为基础材料,配制稳定剂;将稳定剂与缓冲液分别以体积比0.5:99.5、5:95,以及1.75:98.25的比例分别配成样本处理试剂;取0.005ml新鲜血液样本,加入到0.495ml样本处理试剂中,混匀并反应1分钟;再加入10ul商品化的瑞吉氏染色液,混匀后镜检拍照。图5至图7分别是实施例4至实施例6中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片。In embodiment 4 to embodiment 6, can show the influence of different stabilizing agent contents on sample pretreatment; In embodiment 4 to embodiment 6, take 50% glutaraldehyde and 37% formaldehyde as base material, prepare Stabilizer; the stabilizer and the buffer solution are formulated into sample processing reagents at volume ratios of 0.5:99.5, 5:95, and 1.75:98.25 respectively; take 0.005ml of fresh blood samples and add them to 0.495ml of sample processing reagents, Mix well and react for 1 minute; then add 10ul of commercial Regis staining solution, mix well and take pictures under microscope. Figures 5 to 7 are micrographs of the stained cell suspensions obtained after the staining was performed after the pretreatment reagents in Examples 4 to 6 were tiled.
在实施例7至实施例9的前处理试剂制备以及前处理方法和染色方法中,包括以下步骤:In the pretreatment reagent preparation of embodiment 7 to embodiment 9 and pretreatment method and dyeing method, comprise the following steps:
步骤1:将0.2M磷酸二氢盐溶液与0.2M磷酸氢二盐溶液按照体积比28:72的比例混合,配制成PH值等于7.2,浓度为0.2M(摩尔/升)的磷酸缓冲液;步骤2:将0.2M的磷酸缓冲液与纯化水分别按照体积比1:9,5:5,及3:7,稀释成磷酸缓冲液;步骤3:将稳定剂中50%戊二醛溶液与37%甲醛溶液按照体积比等于42.9:57.1的比例混合,得到稳定剂;步骤4:将稳定剂分别加入上述磷酸缓冲液中,磷酸缓冲液与稳定剂的体积比为98.25:1.75,配制成前处理试剂,此时前处理试剂中的磷酸盐浓度分别是0.02M、0.1M与0.06M;pH为7.2;步骤5:取0.005ml新鲜血液样本,加入到0.495ml样本处理试剂中,混匀并反应1分钟;再加入10ul商品化的瑞吉氏染色液,混匀后镜检拍照。图8至图10分别是实施例7至实施例9中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片。Step 1: Mix 0.2M dihydrogen phosphate solution and 0.2M dihydrogen phosphate solution in a volume ratio of 28:72 to prepare a phosphate buffer solution with a pH value equal to 7.2 and a concentration of 0.2M (mol/liter); Step 2: Dilute 0.2M phosphate buffer solution and purified water into phosphate buffer solution according to the volume ratio of 1:9, 5:5, and 3:7 respectively; Step 3: Dilute 50% glutaraldehyde solution in the stabilizer with 37% formaldehyde solution is mixed according to the volume ratio equal to 42.9:57.1 to obtain the stabilizer; Step 4: Add the stabilizer to the above phosphate buffer respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, before preparing Treatment reagent, at this time the phosphate concentration in the pre-treatment reagent is 0.02M, 0.1M and 0.06M respectively; pH is 7.2; Step 5: Take 0.005ml of fresh blood sample, add it to 0.495ml of sample treatment reagent, mix well and React for 1 minute; then add 10ul of commercial Regis staining solution, mix well and take pictures under microscope. Figures 8 to 10 are micrographs of the stained cell suspensions obtained after the staining was performed after the pretreatment reagents in Examples 7 to 9 were tiled.
在实施例10至实施例12中,能看到不同pH值环境对样本前处理的影响;在实施例10至实施例12中,先配制作“0.2M磷酸盐缓冲液体系”。In Examples 10 to 12, the influence of different pH environments on sample pretreatment can be seen; in Examples 10 to 12, the "0.2M phosphate buffer system" is prepared first.
在实施例10至实施例12中,包括以下步骤:In embodiment 10 to embodiment 12, comprise the following steps:
步骤1:先配制0.2M磷酸二氢钠溶液:称取23.99克无水磷酸二氢钠,溶于800毫升纯化水中,定容至1000毫升;Step 1: First prepare 0.2M sodium dihydrogen phosphate solution: weigh 23.99 grams of anhydrous sodium dihydrogen phosphate, dissolve it in 800 ml of purified water, and set the volume to 1000 ml;
步骤2:再配制0.2M磷酸氢二钠溶液;称取28.39克无水磷氢二钠,溶于800毫升纯化水中,定容至1000毫升。Step 2: Prepare a 0.2M disodium hydrogen phosphate solution; weigh 28.39 g of anhydrous disodium phosphate, dissolve it in 800 ml of purified water, and dilute to 1000 ml.
步骤3:再配制最佳0.2M磷酸缓冲液;在实施例10中,将0.2M磷酸二氢钠溶液与0.2M磷酸氢二钠溶液按照28:72的体积比混合,此时0.2M磷酸缓冲液pH值为7.2;在实施例11中,配制0.2M一般范围上限磷酸缓冲液体系,是将0.2M磷酸二氢钠溶液与0.2M磷酸氢二钠溶液按照5.3:94.7的体积比混合,此时0.2M磷酸缓冲液pH值为8.0;在实施例12中,配制0.2M一般范围下限磷酸缓冲液体系,将0.2M磷酸二氢钠溶液与0.2M磷酸氢二钠溶液按照73.5:26.5的体积比混合,此时0.2M磷酸缓冲液pH值为6.4;Step 3: Prepare the optimal 0.2M phosphate buffer solution; in Example 10, mix 0.2M sodium dihydrogen phosphate solution with 0.2M disodium hydrogen phosphate solution in a volume ratio of 28:72, then 0.2M phosphate buffer The pH value of the solution is 7.2; in Example 11, the 0.2M general range upper limit phosphate buffer system was prepared by mixing 0.2M sodium dihydrogen phosphate solution and 0.2M disodium hydrogen phosphate solution according to the volume ratio of 5.3:94.7. When the pH value of 0.2M phosphate buffer was 8.0; in Example 12, the 0.2M general range lower limit phosphate buffer system was prepared, and the 0.2M sodium dihydrogen phosphate solution and the 0.2M disodium hydrogen phosphate solution were according to the volume of 73.5:26.5 Ratio mixing, at this time the pH value of 0.2M phosphate buffer is 6.4;
步骤4:将上述三种0.2M磷酸缓冲液与纯化水按3:7的体积混合,配制成三种不同pH值的缓冲液;Step 4: Mix the above three 0.2M phosphate buffers with purified water in a volume ratio of 3:7 to prepare three buffers with different pH values;
步骤5:再将稳定剂中50%戊二醛溶液与37%甲醛溶液按照体积比等于42.9:57.1的比例混合,得到稳定剂;Step 5: Mix 50% glutaraldehyde solution and 37% formaldehyde solution in the stabilizer according to the volume ratio equal to 42.9:57.1 to obtain the stabilizer;
步骤6:将稳定剂分别加入上述PH值分别为7.2、8.0、6.4的磷酸缓冲液中,磷酸缓冲液与稳定剂的体积比为98.25:1.75,分别配制成实施例10至12的前处理试剂;此时前处理试剂中的磷酸盐浓度是0.06M,此时前处理试剂的pH值分别为7.3、8.1、6.5;Step 6: Add the stabilizer to the above-mentioned phosphate buffer with pH values of 7.2, 8.0, and 6.4 respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, and prepare the pretreatment reagents of Examples 10 to 12 respectively ; Now the phosphate concentration in the pretreatment reagent is 0.06M, and the pH value of the pretreatment reagent is 7.3, 8.1, 6.5 respectively;
步骤7:再取0.005ml新鲜血液样本,加入到0.495ml样本处理试剂中,混匀并反应1分钟;Step 7: Take another 0.005ml fresh blood sample, add it to 0.495ml sample processing reagent, mix well and react for 1 minute;
步骤8:再加入10ul商品化的瑞吉氏染色液,混匀后镜检拍照。图11至图13分别是实施例10至实施例12中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片。Step 8: Add 10ul of commercial Regis staining solution, mix well and take pictures under microscope. Figures 11 to 13 are micrographs of the stained cell suspensions obtained after being stained after being treated with the pretreatment reagents in Examples 10 to 12, respectively.
在实施例13至实施例15的前处理试剂制备以及前处理方法和染色方法中,包括以下步骤:In embodiment 13 to embodiment 15, in the pretreatment reagent preparation and pretreatment method and dyeing method, comprise the following steps:
步骤1:将0.2M磷酸二氢盐溶液与0.2M磷酸氢二盐溶液按照体积比28:72的比例混合,配制成pH值等于7.2,浓度为0.2M(摩尔/升)的磷酸缓冲液;Step 1: Mix 0.2M dihydrogen phosphate solution and 0.2M dihydrogen phosphate solution in a volume ratio of 28:72 to prepare a phosphate buffer solution with a pH value equal to 7.2 and a concentration of 0.2M (mol/liter);
步骤2:将0.2M的磷酸缓冲液与纯化水按照体积比3:7,稀释成磷酸缓冲液;Step 2: Dilute 0.2M phosphate buffer solution and purified water into phosphate buffer solution at a volume ratio of 3:7;
步骤3:将稳定剂中50%戊二醛溶液与无水甲醇溶液分别按照体积比等于20%:80%、42.9%:57.1%、11.1%:88.9%的比例混合,得到稳定剂;Step 3: Mix 50% glutaraldehyde solution and anhydrous methanol solution in the stabilizer according to volume ratios equal to 20%: 80%, 42.9%: 57.1%, 11.1%: 88.9%, respectively, to obtain the stabilizer;
步骤4:将稳定剂分别加入上述磷酸缓冲液中,磷酸缓冲液与稳定剂的体积比为98.25:1.75,配制成前处理试剂;此时前处理试剂中的磷酸盐浓度分别是0.02M、0.1M与0.06M,前处理试剂的PH值为7.2;取0.005ml新鲜血液样本,加入到0.495ml样本处理试剂中,混匀并反应1分钟;再加入10ul商品化的瑞吉氏染色液,混匀后镜检拍照。图14至图16分别是实施例13至实施例15中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片。Step 4: Add the stabilizer to the above-mentioned phosphate buffer respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, and prepare the pretreatment reagent; at this time, the phosphate concentration in the pretreatment reagent is 0.02M, 0.1M M and 0.06M, the pH value of the pretreatment reagent is 7.2; take 0.005ml fresh blood sample, add it to 0.495ml sample treatment reagent, mix and react for 1 minute; then add 10ul of commercial Regis staining solution, mix After uniformity, take pictures under the microscope. Figures 14 to 16 are micrographs of the stained cell suspensions obtained after the staining was performed after the pretreatment reagents in Examples 13 to 15 were tiled.
在实施例16至实施例18的前处理试剂制备以及前处理方法和染色方法中,包括以下步骤:In embodiment 16 to embodiment 18 in the pretreatment reagent preparation and pretreatment method and dyeing method, comprise the following steps:
步骤1:将0.2M磷酸二氢盐溶液与0.2M磷酸氢二盐溶液按照体积比28:72的比例混合,配制成pH值等于7.2,浓度为0.2M(摩尔/升)的磷酸缓冲液;Step 1: Mix 0.2M dihydrogen phosphate solution and 0.2M dihydrogen phosphate solution in a volume ratio of 28:72 to prepare a phosphate buffer solution with a pH value equal to 7.2 and a concentration of 0.2M (mol/liter);
步骤2:将0.2M的磷酸缓冲液与纯化水按照体积比3:7,稀释成磷酸缓冲液;Step 2: Dilute 0.2M phosphate buffer solution and purified water into phosphate buffer solution at a volume ratio of 3:7;
步骤3:将稳定剂中50%戊二醛溶液与无水乙醇溶液分别按照体积比等于20%:80%、42.9%:57.1%、11.1%:88.9%的比例混合,得到稳定剂;Step 3: Mix 50% glutaraldehyde solution and absolute ethanol solution in the stabilizer according to volume ratios equal to 20%: 80%, 42.9%: 57.1%, 11.1%: 88.9%, respectively, to obtain the stabilizer;
步骤4:将稳定剂分别加入上述磷酸缓冲液中,磷酸缓冲液与稳定剂的体积比为98.25:1.75,配制成实施例16至18的前处理试剂,此时前处理试剂中的磷酸盐浓度均是0.06M,pH值为7.3;Step 4: Add the stabilizer to the above-mentioned phosphate buffer respectively, the volume ratio of the phosphate buffer to the stabilizer is 98.25:1.75, and it is prepared into the pretreatment reagents of Examples 16 to 18. At this time, the phosphate concentration in the pretreatment reagent Both are 0.06M, and the pH value is 7.3;
步骤5:取0.005ml新鲜血液样本,加入到0.495ml样本处理试剂中,混匀并反应1分钟;再加入10ul商品化的瑞吉氏染色液,混匀后镜检拍照。图17至图19分别是实施例16至实施例18中的前处理试剂处理后再进行染色后获得的染色后细胞悬浮液在平铺后获得的显微图片。Step 5: Take 0.005ml of fresh blood sample, add it to 0.495ml of sample processing reagent, mix well and react for 1 minute; then add 10ul of commercial Regis staining solution, mix well and take pictures under microscope. Figures 17 to 19 are micrographs of the stained cell suspensions obtained after the staining was performed after the pretreatment reagents in Examples 16 to 18 were tiled.
本申请中的前处理试剂以及前处理方法,细胞染色试剂和方法中,其技术效果包括多个方面。新鲜的体液或分泌物样本,其内的细胞具有生物活性。本申请的前处理,能在细胞膜表面膜蛋白发生交联,使在细胞膜表面形成网状结构,保持细胞形态,同时破坏细胞膜的磷脂双分子层,增加细胞膜的透过性;这样对细胞膜的特性进行了处理,一方面能保持好的细胞形态,同时借保持细胞形态也保持了细胞内部物质的活性,使细胞内部的内环境比较接近细胞原始的生理环境,细胞内部的细胞器活性保持的时间会更长。在染色液进入细胞内部后,能发挥细胞内部细胞器的活性,达到对细胞快速染色的目的。Among the pretreatment reagents and pretreatment methods, cell staining reagents and methods in the present application, the technical effects include multiple aspects. A fresh sample of body fluid or secretion in which the cells are biologically active. The pretreatment of the present application can cross-link the membrane protein on the surface of the cell membrane to form a network structure on the surface of the cell membrane to maintain the cell shape, while destroying the phospholipid bilayer of the cell membrane and increasing the permeability of the cell membrane; After treatment, on the one hand, it can maintain a good cell shape, and at the same time, by maintaining the cell shape, it also maintains the activity of the internal substances in the cell, so that the internal environment inside the cell is closer to the original physiological environment of the cell, and the time for maintaining the activity of the organelles inside the cell will be longer. longer. After the staining solution enters the cell, it can exert the activity of the internal organelles of the cell and achieve the purpose of rapidly staining the cell.
本申请设计的细胞染色试剂和染色方法,能在体液或分泌物在液态的悬浮液中完成细胞染色。其适用的样本包括各种生物体液如血液,分泌物如尿液或白带等。The cell staining reagent and staining method designed in the present application can complete cell staining in body fluid or secretion in liquid suspension. Its applicable samples include various biological fluids such as blood, secretions such as urine or leucorrhea, etc.
本申请中的细胞染色方法,待染色样本中的细胞是在液态的悬浮液中完成染色过程,且用于染色液及稀释液的环境为比较接近生物生理状态,因此在染色过程中,细胞活性保持的较好,一方面能利用细胞与溶液中染料分子共同的布朗运动,及静电作用力,进行染色反应,染色速度更快,效率更高;另一方面,由于在这样的染色环境下,细胞活性保持的比较好,通过前处理后的待染色样本,能实现快速均衡的细胞染色,特别适用于活体细胞染色的前处理,能大大提高细胞染色效率。In the cell staining method in this application, the cells in the sample to be stained complete the staining process in a liquid suspension, and the environment used for the staining solution and diluent is relatively close to the biological physiological state, so in the staining process, the cell activity On the one hand, it can use the Brownian motion of the cells and the dye molecules in the solution and the electrostatic force to carry out the dyeing reaction, and the dyeing speed is faster and the efficiency is higher; on the other hand, due to such a dyeing environment, The cell viability is kept relatively well, and fast and balanced cell staining can be achieved through the pre-treated samples to be stained. It is especially suitable for the pre-treatment of live cell staining, which can greatly improve the efficiency of cell staining.
本申请中的方法,样品染色试剂和样品之间的配比的比率设定合理,能对样本中的活体细胞进行染色,操作简单、染色快、染色效果更好,染色结果更有利于细胞形态和种类鉴别,其染色后的溶液可直接适用于明场下的细胞形态分析和检测,并能根据染色后的细胞形态和图形特征分析,进一步地进行细胞分类和细胞分类计数。In the method of this application, the ratio between the sample staining reagent and the sample is set reasonably, and the living cells in the sample can be stained. The operation is simple, the staining is fast, the staining effect is better, and the staining result is more conducive to the shape of the cells. The stained solution can be directly applied to the analysis and detection of cell morphology under bright field, and can further carry out cell classification and cell classification counting according to the analysis of the stained cell morphology and graphic characteristics.
在医疗应用领域还未见在让细胞在溶液状态中,对血液样本进行体外活染,即采用带有色基团的化合物染料,对血液细胞进行直接染色,并依据血液细胞在明视场显微镜下的染色结果中所呈现的细胞特征进行细胞分类分析。本申请方法染色后的体液或分泌物,其所呈现的细胞特征包括细胞的大小、颜色、形态、细胞核的形状、颜色、胞浆的颜色、胞浆内颗粒物的颜色、多少。本申请中的染色后的样本适用于细胞的形态学分析,基于细胞特征的分析如细胞形态和染色的着色度,可以进行细胞的分类识别和计数。In the field of medical applications, it has not been seen that cells are in a solution state to carry out live dyeing of blood samples in vitro, that is, using compound dyes with chromophores to directly stain blood cells, and based on blood cells under a bright field microscope The cell characteristics presented in the staining results were analyzed for cell classification. The body fluids or secretions stained by the method of the present application show cell characteristics including the size, color, shape, shape and color of the nucleus, the color of the cytoplasm, the color and the number of particles in the cytoplasm. The stained sample in this application is suitable for morphological analysis of cells, based on the analysis of cell characteristics such as cell morphology and coloring degree of staining, cell classification, identification and counting can be performed.
相比现有技术中的染色方法、试剂,本申请的主要特色在于,本申请在染色时,样本细胞的状态是处于生理或接近生理的状态。相比现有技术中的染色方法、试剂,本申请的主要特色还在于,染色时的反应环境与操作完全不一样,本申请中不涉及干燥和清洗的流程;本申请中,样本中的细胞一直处于液体溶液环境,用前处理试剂地样本进行前处理后,使各种待染色的目标细胞具有较为均衡的被染色特征,进行染色反应,染色效率更高,不同细胞着色效率更均衡。Compared with the staining methods and reagents in the prior art, the main feature of the present application is that the state of the sample cells is in a physiological or close to physiological state when staining in the present application. Compared with the dyeing methods and reagents in the prior art, the main feature of this application is that the reaction environment during dyeing is completely different from the operation, and this application does not involve the process of drying and cleaning; in this application, the cells in the sample Always in a liquid solution environment, after pretreatment with the sample of pretreatment reagents, various target cells to be stained have more balanced staining characteristics, and the staining reaction is carried out, the staining efficiency is higher, and the staining efficiency of different cells is more balanced.
上述试剂和方法能对样本中的活性细胞进行高效的前处理和高效染色,对操作者的要求不高、染色均匀、耗时短,能实现傻瓜化的染色过程;避免了现有技术中细胞染色操作繁琐,专业要求高,耗时长,易染色不均,染色材料成本高的不足之处。前处理和染色操作简单,能实现傻瓜式的染色操作,使其适用于多种应用场景。如即时检验这样的场景,也适用于急救、床边,战地等多种缺乏大型专业设备、专业人员及复杂检验环境的应用场景。The above reagents and methods can perform efficient pretreatment and efficient staining of the active cells in the sample, have low requirements on the operator, uniform staining, and short time-consuming, and can realize a foolish staining process; avoiding the need for cells in the prior art The dyeing operation is cumbersome, the professional requirements are high, the time is long, the dyeing is easy to be uneven, and the dyeing material cost is high. The pretreatment and dyeing operations are simple, and can realize fool-like dyeing operations, making it suitable for various application scenarios. Scenarios such as instant inspection are also applicable to various application scenarios that lack large-scale professional equipment, professionals, and complex inspection environments, such as first aid, bedside, and battlefield.
以上所述仅为本申请的实施例,并非因此限制本申请的专利范围,凡是利用发明说明书及附图内容所作的等效结构或等效流程变换,或直接或间接运用在其他相关的技术领域,均同理包括在本申请的专利保护范围内。The above is only an embodiment of the application, and does not limit the patent scope of the application. Any equivalent structure or equivalent process conversion made by using the description of the invention and the contents of the accompanying drawings, or directly or indirectly used in other related technical fields , are all included in the patent protection scope of the present application in the same way.

Claims (17)

  1. 一种前处理试剂,其特征在于,A pretreatment reagent, characterized in that,
    用于细胞在悬浮液中染色前的待染色样本前处理,For pretreatment of samples to be stained before cells are stained in suspension,
    其组分,以体积百分比计,包括0.5%-5%稳定剂,95%-99.5%缓冲液。Its components, by volume percentage, include 0.5%-5% stabilizer and 95%-99.5% buffer.
  2. 根据权利要求1所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 1, characterized in that,
    其组分,以体积百分比计,包括1%-3%稳定剂,97%-99%缓冲液。Its components, by volume percentage, include 1%-3% stabilizer and 97%-99% buffer.
  3. 根据权利要求1或2所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 1 or 2, characterized in that,
    所述前处理试剂的pH值范围为6.5-8.1;The pH range of the pretreatment reagent is 6.5-8.1;
    或所述前处理试剂的pH值范围为6.8-7.6。Or the pH range of the pretreatment reagent is 6.8-7.6.
  4. 根据权利要求1或2所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 1 or 2, characterized in that,
    所述稳定剂的组分,以体积百分比计,包括33.3%-50%戊二醛溶液,50%-66.7%醛类溶液;The components of the stabilizer, in volume percentage, include 33.3%-50% glutaraldehyde solution, 50%-66.7% aldehyde solution;
    或所述稳定剂的组分,以体积百分比计,包括40%-50%戊二醛溶液,50%-60%醛类溶液。Or the components of the stabilizer, by volume percentage, include 40%-50% glutaraldehyde solution and 50%-60% aldehyde solution.
  5. 根据权利要求4所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 4, characterized in that,
    所述醛类溶液中的醛类物质包括甲醛、乙醛、丙醛、多聚甲醛中的任意一种或多种。The aldehyde substances in the aldehyde solution include any one or more of formaldehyde, acetaldehyde, propionaldehyde and paraformaldehyde.
  6. 根据权利要求1或2所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 1 or 2, characterized in that,
    所述稳定剂的组分,以体积百分比计,包括21.1%-48.3%戊二醛溶液,51.7%-88.9%醇类溶液。The components of the stabilizer include, by volume percentage, 21.1%-48.3% glutaraldehyde solution and 51.7%-88.9% alcohol solution.
  7. 根据权利要求6所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 6, characterized in that,
    所述醇类溶液中的醇类物质包括无水甲醇或无水乙醇。Alcohol substances in the alcohol solution include absolute methanol or absolute ethanol.
  8. 根据权利要求4所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 4, characterized in that,
    所述戊二醛溶液是戊二醛的质量百分比为50%的戊二醛溶液;Described glutaraldehyde solution is the glutaraldehyde solution that the mass percent of glutaraldehyde is 50%;
    所述醛类溶液是醛类物质的质量百分比为37%的醛类溶液。The aldehyde solution is an aldehyde solution with a mass percentage of aldehyde substances of 37%.
  9. 根据权利要求1或2所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 1 or 2, characterized in that,
    所述缓冲液的组分,以体积百分比计,包括10%-50%磷酸缓冲液,50%-90%纯化水;The components of the buffer include, by volume percentage, 10%-50% phosphate buffer, 50%-90% purified water;
    或所述缓冲液的组分,以体积百分比计,包括20%-40%磷酸缓冲液,60%-80%纯化水。Or the components of the buffer, by volume percentage, include 20%-40% phosphate buffer, 60%-80% purified water.
  10. 根据权利要求9所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 9, characterized in that,
    所述前处理试剂中,磷酸盐浓度0.02M(摩尔/升)至0.1M(摩尔/升)。In the pretreatment reagent, the concentration of phosphate is 0.02M (mol/liter) to 0.1M (mol/liter).
  11. 根据权利要求9所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 9, characterized in that,
    所述磷酸缓冲液的组分,以体积百分比计,包括5.3%-73.5%磷酸二氢盐溶液和26.5%-94.7%磷酸氢二盐溶液。The components of the phosphate buffer include 5.3%-73.5% dihydrogen phosphate solution and 26.5%-94.7% hydrogen phosphate di-salt solution in volume percentage.
  12. 根据权利要求11所述的前处理试剂,其特征在于,The pretreatment reagent according to claim 11, characterized in that,
    所述磷酸缓冲液的组分,以体积百分比计,包括13%-51%磷酸二氢盐溶液和49%-87%磷酸氢二盐溶液。The components of the phosphate buffer include, by volume percentage, 13%-51% dihydrogen phosphate solution and 49%-87% hydrogen phosphate di-salt solution.
  13. 一种前处理试剂制备方法,其特征在于,A method for preparing a pretreatment reagent, characterized in that,
    用于制备权利要求4所述的前处理试剂,包括以下步骤,For preparing the pretreatment reagent described in claim 4, comprising the following steps,
    步骤D:取戊二醛溶液和醛类溶液以33.3%:66.7%至50%:50%的体积比进行混合,制得稳定剂;Step D: Mix glutaraldehyde solution and aldehyde solution at a volume ratio of 33.3%:66.7% to 50%:50% to prepare a stabilizer;
    步骤E:将步骤D制得的稳定剂和缓冲液以0.5:99.5至5:95的体积比混合制得前处理试剂。Step E: Mix the stabilizer and buffer prepared in step D with a volume ratio of 0.5:99.5 to 5:95 to prepare a pretreatment reagent.
  14. 根据权利要求13所述的前处理试剂制备方法,其特征在于,The preparation method of pretreatment reagent according to claim 13, characterized in that,
    在步骤D之前还包括以下步骤:The following steps are also included before step D:
    步骤A:配制0.2M(摩尔/升)磷酸二氢盐溶液的步骤;称取定量无水磷酸二氢盐,溶于相应容积的纯化水中,定容制得0.2M(摩尔/升)磷酸二氢盐溶液;Step A: the step of preparing 0.2M (mol/liter) dihydrogen phosphate solution; weigh quantitative anhydrous dihydrogen phosphate, dissolve it in a corresponding volume of purified water, and prepare 0.2M (mol/liter) dihydrogen phosphate hydrogen salt solution;
    步骤B:配制0.2M(摩尔/升)磷酸氢二盐溶液的步骤;称取定量无水磷酸氢二盐,溶于相应容积的纯化水中,定容制得0.2M(摩尔/升)磷酸氢二盐溶液;Step B: the step of preparing 0.2M (mol/liter) hydrogen phosphate di-salt solution; weigh quantitative anhydrous hydrogen phosphate di-salt, dissolve it in a corresponding volume of purified water, and prepare 0.2M (mol/liter) hydrogen phosphate di-salt solution;
    步骤C:利用步骤A制得的磷酸二氢盐溶液和步骤B制得的磷酸氢二盐溶液混合配制成pH值为6.4-8.0的磷酸缓冲液;Step C: mixing the dihydrogen phosphate solution prepared in step A and the dihydrogen phosphate di-salt solution prepared in step B to prepare a phosphate buffer solution with a pH value of 6.4-8.0;
    步骤E中所用的缓冲液是步骤C制得的磷酸缓冲液;The buffer used in step E is the phosphate buffer that step C makes;
    磷酸缓冲液的用量配比使制得的前处理试剂中,磷酸盐浓度0.02M(摩尔/升)至0.1M(摩尔/升);前处理试剂pH值范围为6.5-8.1。The dosage ratio of the phosphate buffer is such that in the prepared pretreatment reagent, the phosphate concentration is 0.02M (mol/liter) to 0.1M (mol/liter); the pH value range of the pretreatment reagent is 6.5-8.1.
  15. 一种前处理方法,其特征在于,A pretreatment method, characterized in that,
    使用了权利要求1至12中任意一项所述的前处理试剂对待染色样本进行细胞染色之前的前处理;包括以下步骤:Used the pretreatment reagent described in any one in claim 1 to 12 to carry out the pretreatment before cell staining of the sample to be stained; comprise the following steps:
    步骤1:将待染色样本和前处理试剂以1:49至1:399的体积比混合均匀,完成待染色样本的前处理。Step 1: Mix the sample to be stained and the pretreatment reagent evenly at a volume ratio of 1:49 to 1:399 to complete the pretreatment of the sample to be stained.
  16. 一种细胞染色方法,其特征在于,A cell staining method, characterized in that,
    用于在悬浮液中对细胞进行染色;For staining cells in suspension;
    在加入染色液之前采用了权利要求14中的前处理方法对待染色样本进行了前处理。The pretreatment method in claim 14 is used to pretreat the sample to be dyed before adding the staining solution.
  17. 根据权利要求16所述的细胞染色方法,其特征在于,The cell staining method according to claim 16, characterized in that,
    在悬浮液中加入的染色液包括:瑞吉氏染色液、瑞氏染色液、吉姆萨染色液、新亚甲蓝染色液、煌焦油蓝染色液、迪夫快速染色液中的任意一种或多种。The staining solution added to the suspension includes any one or more of Rigi’s staining solution, Wright’s staining solution, Giemsa staining solution, new methylene blue staining solution, brilliant tar blue staining solution, and Diff’s rapid staining solution kind.
PCT/CN2022/087803 2021-05-21 2022-04-20 Pretreatment reagent, preparation method, cell staining method and pretreatment method WO2022242398A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110558513.4A CN115372107A (en) 2021-05-21 2021-05-21 Pretreatment reagent and preparation method thereof, and cell staining method and pretreatment method
CN202110558513.4 2021-05-21

Publications (1)

Publication Number Publication Date
WO2022242398A1 true WO2022242398A1 (en) 2022-11-24

Family

ID=84058325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/087803 WO2022242398A1 (en) 2021-05-21 2022-04-20 Pretreatment reagent, preparation method, cell staining method and pretreatment method

Country Status (2)

Country Link
CN (1) CN115372107A (en)
WO (1) WO2022242398A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116649330A (en) * 2023-07-17 2023-08-29 深圳市森盈智能科技有限公司 Liquid-based exfoliated cell preservation liquid, kit and application
CN117337827A (en) * 2023-10-18 2024-01-05 温州市倍可特医疗器械有限公司 Method for inhibiting formaldehyde volatilization in tissue fixing liquid and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0727682A (en) * 1993-07-09 1995-01-31 Omron Corp Preparation of cytodiagnostic sample
EP1107665A1 (en) * 1998-08-28 2001-06-20 Uropath PTY. Ltd. Method of diagnosis of prostate cancer
JP2006275985A (en) * 2005-03-30 2006-10-12 Sysmex Corp Method for classifying and counting megakaryocyte
CN102980793A (en) * 2012-11-20 2013-03-20 武汉友芝友生物制药有限公司 Circulating tumor cell dyeing kit and use thereof
CN104337140A (en) * 2013-08-09 2015-02-11 上海派莱星生物技术有限公司 Method for long-term household preservation of individual biological tissue cells and active DNA of individual biological tissue cells
CN106932579A (en) * 2017-03-21 2017-07-07 上海美吉医学检验有限公司 A kind of kit of the liver cancer detection based on liquid biopsy
CN108548771A (en) * 2018-06-11 2018-09-18 天晴干细胞股份有限公司 A kind of cell fixer and its application method for flow cytometer detection
CN109459372A (en) * 2018-10-29 2019-03-12 迪瑞医疗科技股份有限公司 Erythroblast simulation particle and the preparation method and application thereof
CN112113821A (en) * 2020-05-28 2020-12-22 王剑 Multiple staining slide preparation method of cytopathology sample

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0727682A (en) * 1993-07-09 1995-01-31 Omron Corp Preparation of cytodiagnostic sample
EP1107665A1 (en) * 1998-08-28 2001-06-20 Uropath PTY. Ltd. Method of diagnosis of prostate cancer
JP2006275985A (en) * 2005-03-30 2006-10-12 Sysmex Corp Method for classifying and counting megakaryocyte
CN102980793A (en) * 2012-11-20 2013-03-20 武汉友芝友生物制药有限公司 Circulating tumor cell dyeing kit and use thereof
CN104337140A (en) * 2013-08-09 2015-02-11 上海派莱星生物技术有限公司 Method for long-term household preservation of individual biological tissue cells and active DNA of individual biological tissue cells
CN106932579A (en) * 2017-03-21 2017-07-07 上海美吉医学检验有限公司 A kind of kit of the liver cancer detection based on liquid biopsy
CN108548771A (en) * 2018-06-11 2018-09-18 天晴干细胞股份有限公司 A kind of cell fixer and its application method for flow cytometer detection
CN109459372A (en) * 2018-10-29 2019-03-12 迪瑞医疗科技股份有限公司 Erythroblast simulation particle and the preparation method and application thereof
CN112113821A (en) * 2020-05-28 2020-12-22 王剑 Multiple staining slide preparation method of cytopathology sample

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116649330A (en) * 2023-07-17 2023-08-29 深圳市森盈智能科技有限公司 Liquid-based exfoliated cell preservation liquid, kit and application
CN116649330B (en) * 2023-07-17 2024-03-01 深圳市森盈智能科技有限公司 Liquid-based exfoliated cell preservation liquid, kit and application
CN117337827A (en) * 2023-10-18 2024-01-05 温州市倍可特医疗器械有限公司 Method for inhibiting formaldehyde volatilization in tissue fixing liquid and application thereof

Also Published As

Publication number Publication date
CN115372107A (en) 2022-11-22

Similar Documents

Publication Publication Date Title
WO2022242398A1 (en) Pretreatment reagent, preparation method, cell staining method and pretreatment method
JP4212827B2 (en) Bone marrow nucleated cell automatic analysis method
CA1124623A (en) Polymer carrier and method for carrying out scientific, analytic and diagnostic examinations
DK175074B1 (en) Viable cell labeling
CN107167356B (en) Coloring agent capable of quickly developing color after cells in urine are colored and using method thereof
US3884579A (en) Method for counting blood platelets
CN112362435A (en) Cell staining reagent and cell staining method
RU2619784C2 (en) System and kit for cytological specimens acquisition for research
CN107860633B (en) Staining agent for analyzing white blood cells and preparation method thereof
US4714606A (en) Method of staining and identifying cells and compositions thereof
CN109946278A (en) Fluorescent dye DAPI carries out cell DNA to dye quantitative screening for cancer and diagnostic method
Delamater et al. Basic fuchsin as a nuclear stain
CN114563253A (en) Gynecological fluorescent staining solution and preparation method and application thereof
CN107271246B (en) A kind of immune p16INK4a antigens for Thinprep pap test preserve liquid and preparation method thereof
CN106053167A (en) Preparation method of marrow fluid smear
CN112985966A (en) Diluent for analyzing urine visible components and preparation method thereof
CN103884562B (en) Chlorination acetic acid AS-D naphthols esterases(AS-DNCE)Dyeing liquor
CN108351282A (en) The method measured for cell count and viability
CN111157713A (en) Hemolysin for blood analysis, preparation method thereof, reagent and kit
US3553311A (en) Method of producing biological stains and reagents for biochemical determinations using ultrasonic energy
CN106644632B (en) Artificial substratum for cell monolayer tiling
WO2005035736A1 (en) Method of mucus removal and, used therein, cell treatment fluid and storage fluid
CN112098181A (en) Raji staining solution used based on instrumental method and application thereof
CN109668771B (en) Liquid-based exfoliative cell staining solution and staining method thereof
CN105648035B (en) Alpha-naphthol acetate esterase staining kit

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22803723

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23.04.2024)

122 Ep: pct application non-entry in european phase

Ref document number: 22803723

Country of ref document: EP

Kind code of ref document: A1